JAX Mouse Strain Datasheet

B6C3-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax

MMRRC Stock No:: 34829-JAX |; APP/PS1

Transgenic

Repository Live

Overview

Also Known As: APP/PS1

Donating Investigator

Dr. David R Borchelt, University of Florida

Genetic overview

Genetic Background	Generation
	?+F14 (03-JAN-17)

Tg(APPswe,PSEN1dE9)85Dbo

Allele Type
Transgenic (Humanized sequence, Inserted expressed sequence)

View Genetics

Research Applications

Neurobiology Research

View All Research Applications

Details

Detailed Description

Double transgenic mice express a chimeric mouse/human amyloid precursor protein (Mo/HuAPP695swe) and a mutant human presenilin 1 (PS1-dE9) both directed to CNS neurons. Both mutations are associated with early-onset Alzheimer's disease. The "humanized" Mo/HuAPP695swe transgene allows the mice to secrete a human A-beta peptide. Both the transgenic peptide and holoprotein can be detected by antibodies specific for human sequence within this region (Signet Laboratories' monoclonal 6E10 antibody). The included Swedish mutations (K595N/M596L) elevate the amount of A-beta produced from the transgene by favoring processing through the beta-secretase pathway. This "humanized" Mo/HuAPP695swe protein is immunodetected in whole brain protein homogenates. The transgenic mutant human presenilin protein (PS1-dE9), which in high levels displaces detectable endogenous mouse protein, is also immunodetected in whole brain protein homogenates. The donating investigator reports that transgenic mice develop beta-amyloid deposits in brain by six to seven months of age. Between 6 and 15 months of age, mice exhibit a gender-based disparity in beta-amyloid burden.Females develop a 5 fold (Aβ₄₂) and 10 fold (Aβ₄₀) increase in beta-amyloid deposits in the cerebellum by 15 months as compared to males. Accumulation of plaques is more abundant in the molecular layer than in the granular layer. In the cortex, both sexes increase the beta-amyloid burden in parallel (Ordonez-Guiterrez et al. Jnl Alz Dis 2016). These mice may be useful in studies of neurological disorders of the brain, specifically Alzheimer's disease, amyloid plaque formation, and aging.

Hemizygous mice on the C57BL/6 background (N9B6) exhibit a high incidence of seizures, as detected by video-EEG. 25% of transgenic mice, 3 to 3.5 months in age, exhibit at least 1 seizure. By 4.5 months of age, seizure incidence increases to 55%. 10-15% mortality is reported for transgenic mice on the congenic (N9) C57BL/6 background (Minkeviciene et al. J Neurosci. 2009).Hemizygous mice, on the congenic C57BL/6J background (N13), 17-18 weeks in age, exhibit epileptiform discharges as detected by video-EEG. Mortality was 38% (6/16) and some mutant mice experienced spontaneous seizures during the experiments. Antiepileptic drugs (carbamazepine, phenytoin, valproate) reduce the frequency of spontaneous electrographic epileptiform discharges (Ziyatdinova et al. Epilepsy Res 2011). The seizure phenotype is not exhibited on the mixed (B6C3) background.

These animals also display a slight alteration in their tail phenotype (e.g. kinked tail) that is believed to be due to the mixed genetic background of the strain and is not related to transgene expression.

This strain does not carry the retinal degeneration allele Pde6b^rd1.

Development

Two expression plasmids (Mo/HuAPP695swe and PS1-dE9) were designed to each be controlled by independent mouse prion protein (PrP) promoter elements, directing transgene expression predominantly to CNS neurons. The Mo/HuAPP695swe transgene expresses a “humanized” mouse amyloid beta (A4) precursor protein gene modified at three amino acids to reflect the human residues and further modified to contain the K595N/M596L (also called K670N/M671L) mutations linked to familial Alzheimers. The PS1-dE9 transgene expresses a mutant human presenilin 1 carrying the exon-9-deleted variant (PSEN1dE9) associated with familial Alzheimer's disease. These constructs were coinjected into (C57BL/6 x C3H)F2 pronuclei and insertion of the transgenes occured at a single locus. Founder line 85 was obtained and the resulting colony was maintained as a hemizygote.

Expression Data

Expressed Gene	APP, amyloid beta precursor protein, human
Expressed Gene	PSEN1, presenilin 1, human
Site of Expression

Control Suggestions

Noncarrier

Additional Information

Considerations for Choosing Controls

Selected References

Jankowsky JL; Fadale DJ; Anderson J; Xu GM; Gonzales V; Jenkins NA; Copeland NG; Lee MK; Younkin LH; Wagner SL; Younkin SG; Borchelt DR. 2004. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase.. In: . . MGI: J:87691
Jankowsky JL; Slunt HH; Ratovitski T; Jenkins NA; Copeland NG; Borchelt DR. 2001. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies.. In: . . MGI: J:78664
Reiserer RS; Harrison FE; Syverud DC; McDonald MP. 2007. Impaired spatial learning in the APP + PSEN1DeltaE9 bigenic mouse model of Alzheimer's disease.. In: . . MGI: J:116798

View All References

Genetics

Tg(APPswe,PSEN1dE9)85Dbo

Allele Symbol: Tg(APPswe,PSEN1dE9)85Dbo

Allele Name	transgene insertion 85, David R Borchelt
Allele Type	Transgenic (Humanized sequence, Inserted expressed sequence)
Allele Synonym(s)	2xTg Ad; APP-PS1; APP/PS1; APPswe/PS1dE9; APPswe/PS1deltaE9; APdE9; Mo/Hu APPswe PS1dE9; Tg(APPSwe,PSEN1)85Dbo
Gene Symbol and Name	Tg(APPswe,PSEN1dE9)85Dbo, transgene insertion 85, David R Borchelt
Gene Synonym(s)	APP/PS1; APPswe/PS1dE9; APdE9; Mo/Hu APPswe PS1dE9
Promoter	Prn, prion protein readthrough transcript, mouse, laboratory
Expressed Gene	APP, amyloid beta precursor protein, human
Expressed Gene	PSEN1, presenilin 1, human
Strain of Origin	(C57BL/6 x C3H)F2
Chromosome	9
General Note	Mice carrying this double transgene develop beta-amyloid deposits in the brain by 6 to 7 months of age.
Molecular Note	Two transgenes inserted at a single locus in Chromosome 9 between Arpp21 and Pdcd6ip. Each transgene is controlled by the mouse prion promoter and contains a cDNA sequence. In one transgene the cDNA encodes a chimeric amyloid beta (A4) precursor protein (APPswe). In the second transgene the cDNA encodes the "DeltaE9" mutation of human presenilin 1. The DeltaE9 mutation of the human presenilin 1 gene is a deletion of exon 9 and corresponds to a form of early-onset Alzheimer's disease. The amyloid beta precursor protein coding sequences were altered by replacing mouse sequence encoding three amino acids of the A-beta domain with the human coding sequence for these residues. The chimeric amyloid beta (A4) precursor protein sequence was then further modified to encode the Swedish mutations K595N/M596L found in human. Both the transgenic peptide and holoprotein are detected by Signet Laboratories' monoclonal 6E10 antibody, which is specific for human sequence within this region. Human presenilin protein, which in high levels displaces detectable endogenous mouse protein, is immunodetected in the double transgenic mouse in whole brain protein homogenates. Human amyloid precursor protein is also immunodetected in these mice in whole brain protein homogenates.
Mutations Made By	Dr. David Borchelt, University of Florida

Disease/Phenotype

Disease Terms

Research Areas By Genotype

This mouse can be used to support research in many areas including:

Neurobiology Research
- Alzheimer's Disease
  - APP and PSEN1 mutants
  - Presenilin mutants
  - strains expressing mutant APP
- Behavioral and Learning Defects
- Epilepsy
  - electroconvulsive seizures
- Neurodegeneration

Genotype: APP related

Neurobiology Research
- Alzheimer's Disease
- Neurodegeneration

Genotype: Tg(APPswe,PSEN1dE9)85Dbo related

Neurobiology Research
- Alzheimer's Disease

Mammalian Phenotype Terms by Genotype

Genotype: Tg(APPswe,PSEN1dE9)85Dbo/0
B6C3-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax

nervous system phenotype

amyloid beta deposits
- amyloid beta deposition is increased by 2.9-fold as determined by immunohistochemical and morphometric analysis in sucrose-fed mice
- deposits are more extensive in females
- exhibits an overall increase in soluble and insoluble amyloid beta peptide 40 and 42 between 4 and 12 months
- insoluble amyloid beta42 is increased 2-fold in cerebrum of sucrose-fed mice as compared to water-fed control
- level of brain amyloid beta peptide 42 is predominant over 40; levels increase dramatically after 20 weeks of age
- plaques are restricted to cortex and hippocampus at time points up to 12 months of age
- plaques increase in number and size over time
- senile plaques detected by thioflavin S or the anti-amyloid beta antibody, 3D6, as early as 4 months of age
- sparse deposits observed at 21 weeks of age, however, numerous deposits are observed at 45 and 60 weeks
- total amyloid beta levels are increased by 3.6 fold in sucrose fed mice

cerebral amyloid angiopathy
- amyloid deposition is observed in leptomeningeal vasculature
- exhibits progressive increase in cerebral amyloid angiopathy as early as 6 months

behavior/neurological phenotype

abnormal spatial learning
- transgenic mice fed sucrose water failed to learn Morris water maze test after 5 days of training
- water-fed transgenic mice retained some learning ability over 5 day test period, but did not perform as well in the water maze test as non-transgenic controls

increased fluid intake
- mice fed sucrose water exhibited increased water consumption

homeostasis/metabolism phenotype

amyloid beta deposits
- amyloid beta deposition is increased by 2.9-fold as determined by immunohistochemical and morphometric analysis in sucrose-fed mice
- deposits are more extensive in females
- exhibits an overall increase in soluble and insoluble amyloid beta peptide 40 and 42 between 4 and 12 months
- insoluble amyloid beta42 is increased 2-fold in cerebrum of sucrose-fed mice as compared to water-fed control
- level of brain amyloid beta peptide 42 is predominant over 40; levels increase dramatically after 20 weeks of age
- plaques are restricted to cortex and hippocampus at time points up to 12 months of age
- plaques increase in number and size over time
- senile plaques detected by thioflavin S or the anti-amyloid beta antibody, 3D6, as early as 4 months of age
- sparse deposits observed at 21 weeks of age, however, numerous deposits are observed at 45 and 60 weeks
- total amyloid beta levels are increased by 3.6 fold in sucrose fed mice

amyloidosis

cerebral amyloid angiopathy
- amyloid deposition is observed in leptomeningeal vasculature
- exhibits progressive increase in cerebral amyloid angiopathy as early as 6 months

impaired glucose tolerance
- mice fed sucrose water displayed an impaired glucose tolerance as compared to water-fed control

increased circulating cholesterol level
- total cholesterol, but not HDL, levels are increased 30% in mice fed sucrose water as compared to water-fed control

increased circulating insulin level
- fasting plasma insulin levels are increased 3 fold in mice fed sucrose water as compared to water-fed control

increased circulating triglyceride level
- elevated plasma triglyceride levels observed in females at 15 weeks of age

cardiovascular system phenotype

vasculature congestion

growth/size/body region phenotype

increased body weight
- mice fed sucrose water consistently gained weight over study time period (2 months- 8 months)
- sucrose-fed mice increased body weight by 17% over water-fed controls

Genotype: Tg(APPswe,PSEN1dE9)85Dbo/0
involves: C3H/HeJ * C57BL/6J

nervous system phenotype

amyloid beta deposits
- deposits observed in hippocampus by 6 months of age
- occasional deposits can be found in mice as young as 6 months of age
- plaques are abundant in hippocampus and cortex by 9 months of age
- ratio of amyloid beta peptide 40:42 is 0.50:1

reduced long term potentiation
- transient long term potentiation (t-LTP) is reduced in transgenics and is age-independent

behavior/neurological phenotype

abnormal spatial reference memory
- 13 month old transgenic mice commit more errors in the water maze than controls, at 7 months of age both groups test similarly
- transgenic mice exhibit a 4-5% higher preference for the arm of the radial arm water maze that held the platform on the previous day

impaired coordination
- 14 month old transgenic mice exhibit a reduced ability to maintain balance on a rotarod

growth/size/body region phenotype

decreased body weight
- at 14 months, transgenics weigh less than controls

homeostasis/metabolism phenotype

amyloid beta deposits
- deposits observed in hippocampus by 6 months of age
- occasional deposits can be found in mice as young as 6 months of age
- plaques are abundant in hippocampus and cortex by 9 months of age
- ratio of amyloid beta peptide 40:42 is 0.50:1

The following phenotype information is associated with a similar, but not exact match to this JAX^® Mice strain

Genotype: Tg(APPswe,PSEN1dE9)85Dbo/0
involves: C3H * C57BL/6

nervous system phenotype

abnormal medium spiny neuron morphology
- nuclei of medium spiny stellate neurons in both 6 and 12 month old transgenics are smaller and darker than wild-type

decreased neuron number
- numbers of neurons are reduced in striatum of 12, but not 6, month old transgenics

nervous system phenotype
- striatal volume is similar in both transgenic and wild-type at either 6 or 12 months of age

neuron degeneration
- numbers of neurons are reduced in striatum of 12, but not 6, month old transgenics
- reduced neuron density is observed in striatum of 12, but not 6, month old transgenics

homeostasis/metabolism phenotype

amyloidosis
- increase in circulating amyloid beta protein levels

homeostasis/metabolism phenotype
- mutants exhibit normal body weight, blood glucose, plasma insulin levels, nonfasting blood glucose and nonfasting plasma insulin, and normal glucose and insulin tolerance, indicating normal glucose homeostasis and insulin sensitivity

Genotype: Tg(APPswe,PSEN1dE9)85Dbo/0
D2.Cg-Tg(APPswe,PSEN1dE9)85Dbo

homeostasis/metabolism phenotype

amyloid beta deposits
- Background Sensitivity - although hemizygotes do have some ThioS+ plaque deposition in the cortex, there are far fewer plaques than are found in hemizygotes on the C57BL/6J background (average 10 per section versus 58 per section)

hematopoietic system phenotype

microgliosis
- cortical staining finds a slight increase in microglia in hemizygotes compared with DBA/2J controls

mortality/aging

premature death
- Background Sensitivity - There is a much higher rate of premature death in hemizygotes on the DBA/2J background than on the C57BL/6J background, although hemizygotes that survive beyond 6 months of age do not have a high rate of premature death thereafter

immune system phenotype

microgliosis
- cortical staining finds a slight increase in microglia in hemizygotes compared with DBA/2J controls

behavior/neurological phenotype

convulsive seizures
- Background Sensitivity - on the DBA/2J background hemizygotes that die prematurely are found in a lethal seizure pose of clenched front limbs and stretched out hind limbs consistent with the audiogenic seizure-induced death inherent in DBA/2J, but the percentage of hemizygotes found dead is much higher than that in wild type DBA/2J. Consistent with wild-type DBA/2J lethal seizures, premature death is not found in hemizygotes that survive beyond 6 months of age.und dead is much higher than that in wild type DBA/2J. Consistent with wild-type DBA/2J lethal seizures, premature death is not found in hemizygotes that survive beyond 6 months of age.
- despite the increased lethal seizures, the electroconvulsive threshold is not decreased relative to DBA/2J controls

nervous system phenotype

amyloid beta deposits
- Background Sensitivity - although hemizygotes do have some ThioS+ plaque deposition in the cortex, there are far fewer plaques than are found in hemizygotes on the C57BL/6J background (average 10 per section versus 58 per section)

convulsive seizures
- Background Sensitivity - on the DBA/2J background hemizygotes that die prematurely are found in a lethal seizure pose of clenched front limbs and stretched out hind limbs consistent with the audiogenic seizure-induced death inherent in DBA/2J, but the percentage of hemizygotes found dead is much higher than that in wild type DBA/2J. Consistent with wild-type DBA/2J lethal seizures, premature death is not found in hemizygotes that survive beyond 6 months of age.und dead is much higher than that in wild type DBA/2J. Consistent with wild-type DBA/2J lethal seizures, premature death is not found in hemizygotes that survive beyond 6 months of age.
- despite the increased lethal seizures, the electroconvulsive threshold is not decreased relative to DBA/2J controls

microgliosis
- cortical staining finds a slight increase in microglia in hemizygotes compared with DBA/2J controls

nervous system phenotype
- no significant differences are found between hemizygotes and DBA/2J in neuron number in the three different regions of the cortex at 6 months of age, indicating no increase in neuronal cell loss, and the number of cortical astrocytes is normal

Genotype: Tg(APPswe,PSEN1dE9)85Dbo/0
B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax

mortality/aging

premature death
- about 40% of mice are lost by 12 months of age

behavior/neurological phenotype

abnormal spatial learning
- 6 month old mutants exhibit slower visuospatial learning than control mice
- in the visuospatial re-learning test performed at 9, 11, 13, 15, and 18 months of age, mutants exhibit a decrease in the speed of re-learning the task compared to controls
- performance in a morris water maze declines between 3 and 12 months of age
- severely impaired performance in a morris water maze with much longer latencies to reach a hidden platform

convulsive seizures
- Background Sensitivity - premature death early in life eappears to result from convulsive seizures and is much less frequent on the C57BL/6J background than on the DBA/2J background

impaired contextual conditioning behavior
- 4 month old mice infused with a cell-permeable PTEN-PDZ peptide over a period of 3-4 weeks into the brain ventricles show improvement in the contextual fear conditioning tests
- 4 month old mice infused with the specific PTEN inhibitor VO-OHpic into the brain ventricles over a period for 3-4 weeks show improvement in contextual conditioning behavior
- however, VO-OHpic treatment does not affect auditory-cued fear conditioning (hippocampal-independent task), exploratory activity or basal freezing behavior
- mice exhibit decreased freezing to context

impaired passive avoidance behavior

impaired spatial learning
- 4 month old mice infused with a cell-permeable PTEN-PDZ peptide over a period of 3-4 weeks into the brain ventricles show improvement in the novel object-location task
- 4 month old mice infused with the specific PTEN inhibitor VO-OHpic into the brain ventricles over a period for 3-4 weeks show improvement in spatial learning tasks
- mice exhibit impaired behavior in the novel object location task

nervous system phenotype

abnormal CNS synaptic transmission
- VO-OHpic treatment does not rescue the lower basal synaptic transmission
- basal synaptic transmission is lower in hippocampal slices

amyloid beta deposits
- Background Sensitivity - there are more ThioS+ plaques in the cortex on the C57BL/6J background than on the DBA/2J background
- at 2 months of age carriers are indistinguishable from C57BL/6J controls, but at 4 months of age very small plaques are found in the cortex, and at 6 months of age plaques are evident in the cortex and hippocampus

astrocytosis

axon degeneration
- axon degeneration and synapse loss

convulsive seizures
- Background Sensitivity - premature death early in life eappears to result from convulsive seizures and is much less frequent on the C57BL/6J background than on the DBA/2J background

reduced long term potentiation
- semi-chronic treatment with VO-OHpic fully rescues LTP levels in hippocampal slices

taste/olfaction phenotype

taste/olfaction phenotype
- mutants do not exhibit Alzheimer's disease-related impairments in olfactory performance in tests based on an operant conditioning procedure and in tests based on a habituation/dishabituation procedure

homeostasis/metabolism phenotype

amyloid beta deposits
- Background Sensitivity - there are more ThioS+ plaques in the cortex on the C57BL/6J background than on the DBA/2J background
- at 2 months of age carriers are indistinguishable from C57BL/6J controls, but at 4 months of age very small plaques are found in the cortex, and at 6 months of age plaques are evident in the cortex and hippocampus

The following phenotype relates to a compound genotype created using this strain

Genotype: Hc¹/Hc¹ Tg(APPswe,PSEN1dE9)85Dbo/0
D2.Cg-Tg(APPswe,PSEN1dE9)85Dbo

homeostasis/metabolism phenotype

amyloid beta deposits
- Background Sensitivity - the complement pathway does not impact plaque deposition in the cortex, the number of plaques is the same as that in transgene carriers with the DBA/2J allele of Hc

behavior/neurological phenotype

convulsive seizures
- Background Sensitivity - despite the presence of functional hemolytic complement these mice have the same rate of lethal seizures as transgenics with the non-functional DBA/2J allele

mortality/aging

premature death

nervous system phenotype

amyloid beta deposits
- Background Sensitivity - the complement pathway does not impact plaque deposition in the cortex, the number of plaques is the same as that in transgene carriers with the DBA/2J allele of Hc

convulsive seizures
- Background Sensitivity - despite the presence of functional hemolytic complement these mice have the same rate of lethal seizures as transgenics with the non-functional DBA/2J allele

nervous system phenotype
- no significant differences are found in cortical neuron number in complement deficient versus functional transgene carriers

References

Jankowsky JL; Fadale DJ; Anderson J; Xu GM; Gonzales V; Jenkins NA; Copeland NG; Lee MK; Younkin LH; Wagner SL; Younkin SG; Borchelt DR. 2004. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase.. In: . . MGI: J:87691
Jankowsky JL; Slunt HH; Ratovitski T; Jenkins NA; Copeland NG; Borchelt DR. 2001. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies.. In: . . MGI: J:78664
Reiserer RS; Harrison FE; Syverud DC; McDonald MP. 2007. Impaired spatial learning in the APP + PSEN1DeltaE9 bigenic mouse model of Alzheimer's disease.. In: . . MGI: J:116798

Additional References

Fukui H; Diaz F; Garcia S; Moraes CT. 2007. Cytochrome c oxidase deficiency in neurons decreases both oxidative stress and amyloid formation in a mouse model of Alzheimer's disease. In: . . MGI: J:123812
Sood A; Warren Beach J; Webster SJ; Terry AV; Buccafusco JJ. 2007. The effects of JWB1-84-1 on memory-related task performance by amyloid Abeta transgenic mice and by young and aged monkeys.. In: . . MGI: J:124366

Additional - Tg(APPswe,PSEN1dE9)85Dbo related

Akhter H; Ballinger C; Liu N; van Groen T; Postlethwait EM; Liu RM. 2015. Cyclic Ozone Exposure Induces Gender-Dependent Neuropathology and Memory Decline in an Animal Model of Alzheimer's Disease.. In: . . MGI: J:228235
Ansoleaga B; Garcia-Esparcia P; Llorens F; Moreno J; Aso E; Ferrer I. 2013. Dysregulation of brain olfactory and taste receptors in AD, PSP and CJD, and AD-related model.. In: . . MGI: J:207052
Bae M; Patel N; Xu H; Lee M; Tominaga-Yamanaka K; Nath A; Geiger J; Gorospe M; Mattson MP; Haughey NJ. 2014. Activation of TRPML1 clears intraneuronal Abeta in preclinical models of HIV infection.. In: . . MGI: J:216162
Bakalash S; Pham M; Koronyo Y; Salumbides BC; Kramerov A; Seidenberg H; Berel D; Black KL; Koronyo-Hamaoui M. 2011. Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease.. In: . . MGI: J:189462
Bao XQ; Li N; Wang T; Kong XC; Tai WJ; Sun H; Zhang D. 2013. FLZ alleviates the memory deficits in transgenic mouse model of Alzheimer's disease via decreasing beta-amyloid production and tau hyperphosphorylation.. In: . . MGI: J:209326
Barbero-Camps E; Fernandez A; Baulies A; Martinez L; Fernandez-Checa JC; Colell A. 2014. Endoplasmic Reticulum Stress Mediates Amyloid beta Neurotoxicity via Mitochondrial Cholesterol Trafficking.. In: . . MGI: J:211660
Barbero-Camps E; Fernandez A; Martinez L; Fernandez-Checa JC; Colell A. 2013. APP/PS1 mice overexpressing SREBP-2 exhibit combined Abeta accumulation and tau pathology underlying Alzheimer's disease.. In: . . MGI: J:199130
Baron R; Babcock AA; Nemirovsky A; Finsen B; Monsonego A. 2014. Accelerated microglial pathology is associated with Abeta plaques in mouse models of Alzheimer's disease.. In: . . MGI: J:215081
Baruch K; Deczkowska A; Rosenzweig N; Tsitsou-Kampeli A; Sharif AM; Matcovitch-Natan O; Kertser A; David E; Amit I; Schwartz M. 2016. PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer's disease.. In: . . MGI: J:233342
Baruch K; Kertser A; Porat Z; Schwartz M. 2015. Cerebral nitric oxide represses choroid plexus NFkappaB-dependent gateway activity for leukocyte trafficking.. In: . . MGI: J:222768
Ben Haim L; Ceyzeriat K; Carrillo-de Sauvage MA; Aubry F; Auregan G; Guillermier M; Ruiz M; Petit F; Houitte D; Faivre E; Vandesquille M; Aron-Badin R; Dhenain M; Deglon N; Hantraye P; Brouillet E; Bonvento G; Escartin C. 2015. The JAK/STAT3 pathway is a common inducer of astrocyte reactivity in Alzheimer's and Huntington's diseases.. In: . . MGI: J:219873
Bennett L; Kersaitis C; Macaulay SL; Munch G; Niedermayer G; Nigro J; Payne M; Sheean P; Vallotton P; Zabaras D; Bird M. 2013. Vitamin D2-enriched button mushroom (Agaricus bisporus) improves memory in both wild type and APPswe/PS1dE9 transgenic mice.. In: . . MGI: J:209189
Bennett RE; DeVos SL; Dujardin S; Corjuc B; Gor R; Gonzalez J; Roe AD; Frosch MP; Pitstick R; Carlson GA; Hyman BT. 2017. Enhanced Tau Aggregation in the Presence of Amyloid beta.. In: . . MGI: J:243583
Bernardo A; Harrison FE; McCord M; Zhao J; Bruchey A; Davies SS; Jackson Roberts L 2nd; Mathews PM; Matsuoka Y; Ariga T; Yu RK; Thompson R; McDonald MP. 2009. Elimination of GD3 synthase improves memory and reduces amyloid-beta plaque load in transgenic mice.. In: . . MGI: J:152957
Bero AW; Yan P; Roh JH; Cirrito JR; Stewart FR; Raichle ME; Lee JM; Holtzman DM. 2011. Neuronal activity regulates the regional vulnerability to amyloid-beta deposition.. In: . . MGI: J:173925
Bettayeb K; Hooli BV; Parrado AR; Randolph L; Varotsis D; Aryal S; Gresack J; Tanzi RE; Greengard P; Flajolet M. 2016. Relevance of the COPI complex for Alzheimer's disease progression in vivo.. In: . . MGI: J:232198
Bie B; Wu J; Yang H; Xu JJ; Brown DL; Naguib M. 2014. Epigenetic suppression of neuroligin 1 underlies amyloid-induced memory deficiency.. In: . . MGI: J:207977
Blanch M; Mosquera JL; Ansoleaga B; Ferrer I; Barrachina M. 2016. Altered Mitochondrial DNA Methylation Pattern in Alzheimer Disease-Related Pathology and in Parkinson Disease.. In: . . MGI: J:229984
Bollen E; Vanmierlo T; Akkerman S; Wouters C; Steinbusch HM; Prickaerts J. 2013. 7,8-Dihydroxyflavone improves memory consolidation processes in rats and mice.. In: . . MGI: J:202462
Bonardi C; Pardon MC; Armstrong P. 2016. Deficits in object-in-place but not relative recency performance in the APPswe/PS1dE9 mouse model of Alzheimer's disease: Implications for object recognition.. In: . . MGI: J:242520
Bosomworth HJ; Adlard PA; Ford D; Valentine RA. 2013. Altered expression of ZnT10 in Alzheimer's disease brain.. In: . . MGI: J:200782
Brendel M; Jaworska A; Griessinger E; Rotzer C; Burgold S; Gildehaus FJ; Carlsen J; Cumming P; Baumann K; Haass C; Steiner H; Bartenstein P; Herms J; Rominger A. 2015. Cross-sectional comparison of small animal [18F]-florbetaben amyloid-PET between transgenic AD mouse models.. In: . . MGI: J:226301
Burdo JR; Chen Q; Calcutt NA; Schubert D. 2009. The pathological interaction between diabetes and presymptomatic Alzheimer's disease.. In: . . MGI: J:155161
Burgess BL; McIsaac SA; Naus KE; Chan JY; Tansley GH; Yang J; Miao F; Ross CJ; van Eck M; Hayden MR; van Nostrand W; St George-Hyslop P; Westaway D; Wellington CL. 2006. Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant A beta in plasma.. In: . . MGI: J:113199
Butler D; Hwang J; Estick C; Nishiyama A; Kumar SS; Baveghems C; Young-Oxendine HB; Wisniewski ML; Charalambides A; Bahr BA. 2011. Protective effects of positive lysosomal modulation in Alzheimer's disease transgenic mouse models.. In: . . MGI: J:174789
Butovsky O; Kunis G; Koronyo-Hamaoui M; Schwartz M. 2007. Selective ablation of bone marrow-derived dendritic cells increases amyloid plaques in a mouse Alzheimer's disease model.. In: . . MGI: J:127277
Camboni M; Wang CM; Miranda C; Yoon JH; Xu R; Zygmunt D; Kaspar BK; Martin PT. 2013. Active and passive immunization strategies based on the SDPM1 peptide demonstrate pre-clinical efficacy in the APPswePSEN1dE9 mouse model for Alzheimer's disease.. In: . . MGI: J:201828
Cao D; Lu H; Lewis TL; Li L. 2007. Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease.. In: . . MGI: J:129021
Ceglia I; Reitz C; Gresack J; Ahn JH; Bustos V; Bleck M; Zhang X; Martin G; Simon SM; Nairn AC; Greengard P; Kim Y. 2015. APP intracellular domain-WAVE1 pathway reduces amyloid-beta production.. In: . . MGI: J:228804
Chakravarthy B; Ito S; Atkinson T; Gaudet C; Menard M; Brown L; Whitfield J. 2014. Evidence that a synthetic amyloid-ss oligomer-binding peptide (ABP) targets amyloid-ss deposits in transgenic mouse brain and human Alzheimer's disease brain.. In: . . MGI: J:219135
Chakravarthy B; Menard M; Brown L; Hewitt M; Atkinson T; Whitfield J. 2013. A synthetic peptide corresponding to a region of the human pericentriolar material 1 (PCM-1) protein binds beta-amyloid (Abeta1-42 ) oligomers.. In: . . MGI: J:199628
Chang JY; Lee MH; Lin SR; Yang LY; Sun HS; Sze CI; Hong Q; Lin YS; Chou YT; Hsu LJ; Jan MS; Gong CX; Chang NS. 2015. Trafficking protein particle complex 6A delta (TRAPPC6ADelta) is an extracellular plaque-forming protein in the brain.. In: . . MGI: J:238174
Chen J; Li S; Sun W; Li J. 2015. Anti-diabetes drug pioglitazone ameliorates synaptic defects in AD transgenic mice by inhibiting cyclin-dependent kinase5 activity.. In: . . MGI: J:233495
Chen L; Choi JJ; Choi YJ; Hennig B; Toborek M. 2012. HIV-1 Tat-induced cerebrovascular toxicity is enhanced in mice with amyloid deposits.. In: . . MGI: J:188199
Chen L; Na R; Boldt E; Ran Q. 2015. NLRP3 inflammasome activation by mitochondrial reactive oxygen species plays a key role in long-term cognitive impairment induced by paraquat exposure.. In: . . MGI: J:226283
Chen SQ; Cai Q; Shen YY; Wang PJ; Teng GJ; Zhang W; Zang FC. 2012. Age-related changes in brain metabolites and cognitive function in APP/PS1 transgenic mice.. In: . . MGI: J:193519
Chen Y; Peng Y; Che P; Gannon M; Liu Y; Li L; Bu G; van Groen T; Jiao K; Wang Q. 2014. alpha2A adrenergic receptor promotes amyloidogenesis through disrupting APP-SorLA interaction.. In: . . MGI: J:216651
Cheng D; Logge W; Low JK; Garner B; Karl T. 2013. Novel behavioural characteristics of the APP(Swe)/PS1DeltaE9 transgenic mouse model of Alzheimer's disease.. In: . . MGI: J:197461
Cheng S; Cao D; Hottman DA; Yuan L; Bergo MO; Li L. 2013. Farnesyltransferase haplodeficiency reduces neuropathology and rescues cognitive function in a mouse model of Alzheimer disease.. In: . . MGI: J:207213
Cheng S; LeBlanc KJ; Li L. 2014. Triptolide preserves cognitive function and reduces neuropathology in a mouse model of Alzheimer's disease.. In: . . MGI: J:223474
Cheng S; Wani WY; Hottman DA; Jeong A; Cao D; LeBlanc KJ; Saftig P; Zhang J; Li L. 2017. Haplodeficiency of Cathepsin D does not affect cerebral amyloidosis and autophagy in APP/PS1 transgenic mice.. In: . . MGI: J:243211
Cherry JD; Liu B; Frost JL; Lemere CA; Williams JP; Olschowka JA; O'Banion MK. 2012. Galactic cosmic radiation leads to cognitive impairment and increased abeta plaque accumulation in a mouse model of Alzheimer's disease.. In: . . MGI: J:195722
Choi J; Gao J; Kim J; Hong C; Kim J; Tontonoz P. 2015. The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and Abeta amyloidosis.. In: . . MGI: J:234130
Choi SH; Leight SN; Lee VM; Li T; Wong PC; Johnson JA; Saraiva MJ; Sisodia SS. 2007. Accelerated Abeta deposition in APPswe/PS1deltaE9 mice with hemizygous deletions of TTR (transthyretin).. In: . . MGI: J:122976
Choi SW; Gerencser AA; Ng R; Flynn JM; Melov S; Danielson SR; Gibson BW; Nicholls DG; Bredesen DE; Brand MD. 2012. No consistent bioenergetic defects in presynaptic nerve terminals isolated from mouse models of Alzheimer's disease.. In: . . MGI: J:192812
Chow HM; Guo D; Zhou JC; Zhang GY; Li HF; Herrup K; Zhang J. 2014. CDK5 activator protein p25 preferentially binds and activates GSK3beta.. In: . . MGI: J:216662
Cisternas P; Lindsay CB; Salazar P; Silva-Alvarez C; Retamales RM; Serrano FG; Vio CP; Inestrosa NC. 2015. The increased potassium intake improves cognitive performance and attenuates histopathological markers in a model of Alzheimer's disease.. In: . . MGI: J:231395
Clarke JR; Lyra E Silva NM; Figueiredo CP; Frozza RL; Ledo JH; Beckman D; Katashima CK; Razolli D; Carvalho BM; Frazao R; Silveira MA; Ribeiro FC; Bomfim TR; Neves FS; Klein WL; Medeiros R; LaFerla FM; Carvalheira JB; Saad MJ; Munoz DP; Velloso LA; Ferreira ST; De Felice FG. 2015. Alzheimer-associated Abeta oligomers impact the central nervous system to induce peripheral metabolic deregulation.. In: . . MGI: J:232678
Cohen E; Paulsson JF; Blinder P; Burstyn-Cohen T; Du D; Estepa G; Adame A; Pham HM; Holzenberger M; Kelly JW; Masliah E; Dillin A. 2009. Reduced IGF-1 signaling delays age-associated proteotoxicity in mice.. In: . . MGI: J:157007
Collins JM; King AE; Woodhouse A; Kirkcaldie MT; Vickers JC. 2015. The effect of focal brain injury on beta-amyloid plaque deposition, inflammation and synapses in the APP/PS1 mouse model of Alzheimer's disease.. In: . . MGI: J:221130
Couch BA; Kerrisk ME; Kaufman AC; Nygaard HB; Strittmatter SM; Koleske AJ. 2013. Delayed amyloid plaque deposition and behavioral deficits in outcrossed AbetaPP/PS1 mice.. In: . . MGI: J:195179
Cramer PE; Cirrito JR; Wesson DW; Lee CY; Karlo JC; Zinn AE; Casali BT; Restivo JL; Goebel WD; James MJ; Brunden KR; Wilson DA; Landreth GE. 2012. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models.. In: . . MGI: J:181688
Crouch PJ; Hung LW; Adlard PA; Cortes M; Lal V; Filiz G; Perez KA; Nurjono M; Caragounis A; Du T; Laughton K; Volitakis I; Bush AI; Li QX; Masters CL; Cappai R; Cherny RA; Donnelly PS; White AR; Barnham KJ. 2009. Increasing Cu bioavailability inhibits Abeta oligomers and tau phosphorylation.. In: . . MGI: J:143873
Cui W; Sun Y; Wang Z; Xu C; Peng Y; Li R. 2012. Liver X receptor activation attenuates inflammatory response and protects cholinergic neurons in APP/PS1 transgenic mice.. In: . . MGI: J:184718
Currais A; Prior M; Dargusch R; Armando A; Ehren J; Schubert D; Quehenberger O; Maher P. 2014. Modulation of p25 and inflammatory pathways by fisetin maintains cognitive function in Alzheimer's disease transgenic mice.. In: . . MGI: J:216105
D'Amico M; Di Filippo C; Marfella R; Abbatecola AM; Ferraraccio F; Rossi F; Paolisso G. 2010. Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice.. In: . . MGI: J:158446
Deyts C; Clutter M; Herrera S; Jovanovic N; Goddi A; Parent AT. 2016. Loss of presenilin function is associated with a selective gain of APP function.. In: . . MGI: J:234011
Ding Y; Qiao A; Wang Z; Goodwin JS; Lee ES; Block ML; Allsbrook M; McDonald MP; Fan GH. 2008. Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model.. In: . . MGI: J:143199
Donmez G; Wang D; Cohen DE; Guarente L. 2010. SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10.. In: . . MGI: J:163978
Du J; Sun B; Chen K; Fan L; Wang Z. 2009. Antagonist of peroxisome proliferator-activated receptor gamma induces cerebellar amyloid-beta levels and motor dysfunction in APP/PS1 transgenic mice.. In: . . MGI: J:150592
Du J; Sun B; Chen K; Zhang L; Liu S; Gu Q; Fan L; Zhao N; Wang Z. 2009. Metabolites of cerebellar neurons and hippocampal neurons play opposite roles in pathogenesis of Alzheimer's disease.. In: . . MGI: J:148883
Duffy AM; Holscher C. 2013. The incretin analogue D-Ala(2)GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer's disease.. In: . . MGI: J:194003
Duran-Aniotz C; Morales R; Moreno-Gonzalez I; Hu PP; Fedynyshyn J; Soto C. 2014. Aggregate-depleted brain fails to induce Abeta deposition in a mouse model of Alzheimer's disease.. In: . . MGI: J:212939
Fan LF; Xu DE; Wang WH; Yan K; Wu H; Yao XQ; Xu RX; Liu CF; Ma QH. 2013. Caspr interaction with Amyloid Precursor Protein reduces amyloid-beta generation in vitro.. In: . . MGI: J:201534
Ferguson SA; Sarkar S; Schmued LC. 2013. Longitudinal behavioral changes in the APP/PS1 transgenic Alzheimer's disease model.. In: . . MGI: J:197158
Fine JM; Renner DB; Forsberg AC; Cameron RA; Galick BT; Le C; Conway PM; Stroebel BM; Frey WH 2nd; Hanson LR. 2015. Intranasal deferoxamine engages multiple pathways to decrease memory loss in the APP/PS1 model of amyloid accumulation.. In: . . MGI: J:218601
Fisher Y; Strominger I; Biton S; Nemirovsky A; Baron R; Monsonego A. 2014. Th1 polarization of T cells injected into the cerebrospinal fluid induces brain immunosurveillance.. In: . . MGI: J:207169
Fitz NF; Cronican AA; Saleem M; Fauq AH; Chapman R; Lefterov I; Koldamova R. 2012. Abca1 Deficiency Affects Alzheimer's Disease-Like Phenotype in Human ApoE4 But Not in ApoE3-Targeted Replacement Mice.. In: . . MGI: J:188282
Frake RA; Ricketts T; Menzies FM; Rubinsztein DC. 2015. Autophagy and neurodegeneration.. In: . . MGI: J:219892
Frenkel D; Wilkinson K; Zhao L; Hickman SE; Means TK; Puckett L; Farfara D; Kingery ND; Weiner HL; El Khoury J. 2013. Scara1 deficiency impairs clearance of soluble amyloid-beta by mononuclear phagocytes and accelerates Alzheimer's-like disease progression.. In: . . MGI: J:221229
Frost JL; Le KX; Cynis H; Ekpo E; Kleinschmidt M; Palmour RM; Ervin FR; Snigdha S; Cotman CW; Saido TC; Vassar RJ; George-Hyslop PS; Ikezu T; Schilling S; Demuth HU; Lemere CA. 2013. Pyroglutamate-3 Amyloid-beta Deposition in the Brains of Humans, Non-Human Primates, Canines, and Alzheimer Disease-Like Transgenic Mouse Models.. In: . . MGI: J:199082
Frost JL; Liu B; Rahfeld JU; Kleinschmidt M; O'Nuallain B; Le KX; Lues I; Caldarone BJ; Schilling S; Demuth HU; Lemere CA. 2015. An anti-pyroglutamate-3 Abeta vaccine reduces plaques and improves cognition in APPswe/PS1DeltaE9 mice.. In: . . MGI: J:232371
Fu AK; Hung KW; Huang H; Gu S; Shen Y; Cheng EY; Ip FC; Huang X; Fu WY; Ip NY. 2014. Blockade of EphA4 signaling ameliorates hippocampal synaptic dysfunctions in mouse models of Alzheimer's disease.. In: . . MGI: J:212169
Fu AK; Hung KW; Yuen MY; Zhou X; Mak DS; Chan IC; Cheung TH; Zhang B; Fu WY; Liew FY; Ip NY. 2016. IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline.. In: . . MGI: J:232212
Galea E; Morrison W; Hudry E; Arbel-Ornath M; Bacskai BJ; Gomez-Isla T; Stanley HE; Hyman BT. 2015. Topological analyses in APP/PS1 mice reveal that astrocytes do not migrate to amyloid-beta plaques.. In: . . MGI: J:228309
Garcia-Alloza M; Borrelli LA; Hyman BT; Bacskai BJ. 2010. Antioxidants have a rapid and long-lasting effect on neuritic abnormalities in APP:PS1 mice.. In: . . MGI: J:168295
Garcia-Alloza M; Borrelli LA; Rozkalne A; Hyman BT; Bacskai BJ. 2007. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. In: . . MGI: J:120785
Garcia-Alloza M; Robbins EM; Zhang-Nunes SX; Prucell SM; Betensky RA; Raju S; Prada C; Greenberg SM; Bacskai BJ; Frosch MP. 2006. Charaterization of amyloid deposition in the APPswe/PS2dE9 mouse model of Alzheimer disease. In: . . MGI: J:113200
Gazit N; Vertkin I; Shapira I; Helm M; Slomowitz E; Sheiba M; Mor Y; Rizzoli S; Slutsky I. 2016. IGF-1 Receptor Differentially Regulates Spontaneous and Evoked Transmission via Mitochondria at Hippocampal Synapses.. In: . . MGI: J:230868
Gimbel DA; Nygaard HB; Coffey EE; Gunther EC; Lauren J; Gimbel ZA; Strittmatter SM. 2010. Memory impairment in transgenic Alzheimer mice requires cellular prion protein.. In: . . MGI: J:160557
Go M; Kou J; Lim JE; Yang J; Fukuchi KI. 2016. Microglial response to LPS increases in wild-type mice during aging but diminishes in an Alzheimer's mouse model: Implication of TLR4 signaling in disease progression.. In: . . MGI: J:239130
Gontier G; George C; Chaker Z; Holzenberger M; Aid S. 2015. Blocking IGF Signaling in Adult Neurons Alleviates Alzheimer's Disease Pathology through Amyloid-beta Clearance.. In: . . MGI: J:226016
Gonzalez-Dominguez R; Garcia-Barrera T; Vitorica J; Gomez-Ariza JL. 2014. Region-specific metabolic alterations in the brain of the APP/PS1 transgenic mice of Alzheimer's disease.. In: . . MGI: J:230468
Gonzalez-Zuniga M; Contreras PS; Estrada LD; Chamorro D; Villagra A; Zanlungo S; Seto E; Alvarez AR. 2014. c-Abl stabilizes HDAC2 levels by tyrosine phosphorylation repressing neuronal gene expression in Alzheimer's disease.. In: . . MGI: J:215541
Goto Y; Niidome T; Hongo H; Akaike A; Kihara T; Sugimoto H. 2008. Impaired muscarinic regulation of excitatory synaptic transmission in the APPswe/PS1dE9 mouse model of Alzheimer's disease.. In: . . MGI: J:134791
Gowrishankar S; Yuan P; Wu Y; Schrag M; Paradise S; Grutzendler J; De Camilli P; Ferguson SM. 2015. Massive accumulation of luminal protease-deficient axonal lysosomes at Alzheimer's disease amyloid plaques.. In: . . MGI: J:223725
Griciuc A; Serrano-Pozo A; Parrado AR; Lesinski AN; Asselin CN; Mullin K; Hooli B; Choi SH; Hyman BT; Tanzi RE. 2013. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta.. In: . . MGI: J:201561
Guillot-Sestier MV; Doty KR; Gate D; Rodriguez J Jr; Leung BP; Rezai-Zadeh K; Town T. 2015. Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology.. In: . . MGI: J:219701
Guo C; Wang T; Zheng W; Shan ZY; Teng WP; Wang ZY. 2013. Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease.. In: . . MGI: J:194436
Guo HB; Cheng YF; Wu JG; Wang CM; Wang HT; Zhang C; Qiu ZK; Xu JP. 2015. Donepezil improves learning and memory deficits in APP/PS1 mice by inhibition of microglial activation.. In: . . MGI: J:221910
Guo W; Sha S; Xing X; Jiang T; Cao Y. 2013. Reduction of cerebral Abeta burden and improvement in cognitive function in Tg-APPswe/PSEN1dE9 mice following vaccination with a multivalent Abeta3-10 DNA vaccine.. In: . . MGI: J:201687
Gurevicius K; Lipponen A; Tanila H. 2013. Increased cortical and thalamic excitability in freely moving APPswe/PS1dE9 mice modeling epileptic activity associated with Alzheimer's disease.. In: . . MGI: J:210154
Halford RW; Russell DW. 2009. Reduction of cholesterol synthesis in the mouse brain does not affect amyloid formation in Alzheimer's disease, but does extend lifespan.. In: . . MGI: J:146447
Hall AM; Throesch BT; Buckingham SC; Markwardt SJ; Peng Y; Wang Q; Hoffman DA; Roberson ED. 2015. Tau-dependent Kv4.2 depletion and dendritic hyperexcitability in a mouse model of Alzheimer's disease.. In: . . MGI: J:221673
Hamilton A; Holscher C. 2012. The effect of ageing on neurogenesis and oxidative stress in the APP(swe)/PS1(deltaE9) mouse model of Alzheimer's disease.. In: . . MGI: J:183242
Hamilton A; Vasefi M; Vander Tuin C; McQuaid RJ; Anisman H; Ferguson SS. 2016. Chronic Pharmacological mGluR5 Inhibition Prevents Cognitive Impairment and Reduces Pathogenesis in an Alzheimer Disease Mouse Model.. In: . . MGI: J:235961
Han X; Tang S; Dong L; Song L; Dong Y; Wang Y; Du Y. 2017. Loss of nitrergic and cholinergic neurons in the enteric nervous system of APP/PS1 transgenic mouse model.. In: . . MGI: J:242090
Harcha PA; Vargas A; Yi C; Koulakoff AA; Giaume C; Saez JC. 2015. Hemichannels Are Required for Amyloid beta-Peptide-Induced Degranulation and Are Activated in Brain Mast Cells of APPswe/PS1dE9 Mice.. In: . . MGI: J:222544
Harris RA; Tindale L; Lone A; Singh O; Macauley SL; Stanley M; Holtzman DM; Bartha R; Cumming RC. 2016. Aerobic Glycolysis in the Frontal Cortex Correlates with Memory Performance in Wild-Type Mice But Not the APP/PS1 Mouse Model of Cerebral Amyloidosis.. In: . . MGI: J:231623
Hazra A; Gu F; Aulakh A; Berridge C; Eriksen JL; Ziburkus J. 2013. Inhibitory neuron and hippocampal circuit dysfunction in an aged mouse model of Alzheimer's disease.. In: . . MGI: J:202168
He G; Luo W; Li P; Remmers C; Netzer WJ; Hendrick J; Bettayeb K; Flajolet M; Gorelick F; Wennogle LP; Greengard P. 2010. Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease.. In: . . MGI: J:163997
Heneka MT; Kummer MP; Stutz A; Delekate A; Schwartz S; Vieira-Saecker A; Griep A; Axt D; Remus A; Tzeng TC; Gelpi E; Halle A; Korte M; Latz E; Golenbock DT. 2013. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice.. In: . . MGI: J:194405
Heneka MT; Nadrigny F; Regen T; Martinez-Hernandez A; Dumitrescu-Ozimek L; Terwel D; Jardanhazi-Kurutz D; Walter J; Kirchhoff F; Hanisch UK; Kummer MP. 2010. Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine.. In: . . MGI: J:158919
Hickman SE; Allison EK; El Khoury J. 2008. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice.. In: . . MGI: J:138606
Hirsch-Reinshagen V; Chan JY; Wilkinson A; Tanaka T; Fan J; Ou G; Maia LF; Singaraja RR; Hayden MR; Wellington CL. 2007. Physiologically regulated transgenic ABCA1 does not reduce amyloid burden or amyloid-beta peptide levels in vivo.. In: . . MGI: J:121674
Hirsch-Reinshagen V; Maia LF; Burgess BL; Blain JF; Naus KE; McIsaac SA; Parkinson PF; Chan JY; Tansley GH; Hayden MR; Poirier J; Van Nostrand W; Wellington CL. 2005. The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease.. In: . . MGI: J:105900
Ho A; Liu X; Sudhof TC. 2008. Deletion of Mint proteins decreases amyloid production in transgenic mouse models of Alzheimer's disease.. In: . . MGI: J:142874
Hong X; Liu J; Zhu G; Zhuang Y; Suo H; Wang P; Huang D; Xu J; Huang Y; Yu M; Bian M; Sheng Z; Fei J; Song H; Behnisch T; Huang F. 2014. Parkin overexpression ameliorates hippocampal long-term potentiation and beta-amyloid load in an Alzheimer's disease mouse model.. In: . . MGI: J:205991
Hooijmans CR; Graven C; Dederen PJ; Tanila H; van Groen T; Kiliaan AJ. 2007. Amyloid beta deposition is related to decreased glucose transporter-1 levels and hippocampal atrophy in brains of aged APP/PS1 mice.. In: . . MGI: J:127348
Hooijmans CR; Rutters F; Dederen PJ; Gambarota G; Veltien A; van Groen T; Broersen LM; Lutjohann D; Heerschap A; Tanila H; Kiliaan AJ. 2007. Changes in cerebral blood volume and amyloid pathology in aged Alzheimer APP/PS1 mice on a docosahexaenoic acid (DHA) diet or cholesterol enriched Typical Western Diet (TWD).. In: . . MGI: J:134833
Hoshino A; Helwig M; Rezaei S; Berridge C; Eriksen JL; Lindberg I. 2014. A novel function for proSAAS as an amyloid anti-aggregant in Alzheimer's disease.. In: . . MGI: J:206615
Hsiao YH; Hung HC; Chen SH; Gean PW. 2014. Social interaction rescues memory deficit in an animal model of Alzheimer's disease by increasing BDNF-dependent hippocampal neurogenesis.. In: . . MGI: J:218747
Hsiao YH; Kuo JR; Chen SH; Gean PW. 2012. Amelioration of social isolation-triggered onset of early Alzheimer's disease-related cognitive deficit by N-acetylcysteine in a transgenic mouse model.. In: . . MGI: J:182319
Hu YS; Long N; Pigino G; Brady ST; Lazarov O. 2013. Molecular mechanisms of environmental enrichment: impairments in Akt/GSK3beta, neurotrophin-3 and CREB signaling.. In: . . MGI: J:202121
Huang XT; Qian ZM; He X; Gong Q; Wu KC; Jiang LR; Lu LN; Zhu ZJ; Zhang HY; Yung WH; Ke Y. 2014. Reducing iron in the brain: a novel pharmacologic mechanism of huperzine A in the treatment of Alzheimer's disease.. In: . . MGI: J:212731
Hudry E; Dashkoff J; Roe AD; Takeda S; Koffie RM; Hashimoto T; Scheel M; Spires-Jones T; Arbel-Ornath M; Betensky R; Davidson BL; Hyman BT. 2013. Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain.. In: . . MGI: J:213540
Israeli E; Yakunin E; Zarbiv Y; Hacohen-Solovich A; Kisos H; Loeb V; Lichtenstein M; Ben-Gedalya T; Sabag O; Pikarsky E; Lorberboum-Galski H; Sharon R. 2011. alpha-Synuclein Expression Selectively Affects Tumorigenesis in Mice Modeling Parkinson's Disease.. In: . . MGI: J:172735
Jackson HM; Onos KD; Pepper KW; Graham LC; Akeson EC; Byers C; Reinholdt LG; Frankel WN; Howell GR. 2015. DBA/2J genetic background exacerbates spontaneous lethal seizures but lessens amyloid deposition in a mouse model of Alzheimer's disease.. In: . . MGI: J:227541
Jackson HM; Soto I; Graham LC; Carter GW; Howell GR. 2013. Clustering of transcriptional profiles identifies changes to insulin signaling as an early event in a mouse model of Alzheimer's disease.. In: . . MGI: J:208080
Jankowsky JL; Younkin LH; Gonzales V; Fadale DJ; Slunt HH; Lester HA; Younkin SG; Borchelt DR. 2007. Rodent A beta modulates the solubility and distribution of amyloid deposits in transgenic mice.. In: . . MGI: J:124804
Jansen D; Zerbi V; Arnoldussen IA; Wiesmann M; Rijpma A; Fang XT; Dederen PJ; Mutsaers MP; Broersen LM; Lutjohann D; Miller M; Joosten LA; Heerschap A; Kiliaan AJ. 2013. Effects of specific multi-nutrient enriched diets on cerebral metabolism, cognition and neuropathology in AbetaPPswe-PS1dE9 mice.. In: . . MGI: J:206018
Jansen D; Zerbi V; Janssen CI; Dederen PJ; Mutsaers MP; Hafkemeijer A; Janssen AL; Nobelen CL; Veltien A; Asten JJ; Heerschap A; Kiliaan AJ. 2013. A longitudinal study of cognition, proton MR spectroscopy and synaptic and neuronal pathology in aging wild-type and AbetaPPswe-PS1dE9 mice.. In: . . MGI: J:200837
Janus C; Flores AY; Xu G; Borchelt DR. 2015. Behavioral abnormalities in APPSwe/PS1dE9 mouse model of AD-like pathology: comparative analysis across multiple behavioral domains.. In: . . MGI: J:226285
Jardanhazi-Kurutz D; Kummer MP; Terwel D; Vogel K; Thiele A; Heneka MT. 2011. Distinct adrenergic system changes and neuroinflammation in response to induced locus ceruleus degeneration in APP/PS1 transgenic mice.. In: . . MGI: J:169872
Jiao SS; Yao XQ; Liu YH; Wang QH; Zeng F; Lu JJ; Liu J; Zhu C; Shen LL; Liu CH; Wang YR; Zeng GH; Parikh A; Chen J; Liang CR; Xiang Y; Bu XL; Deng J; Li J; Xu J; Zeng YQ; Xu X; Xu HW; Zhong JH; Zhou HD; Zhou XF; Wang YJ. 2015. Edaravone alleviates Alzheimer's disease-type pathologies and cognitive deficits.. In: . . MGI: J:220808
Jimenez-Palomares M; Ramos-Rodriguez JJ; Lopez-Acosta JF; Pacheco-Herrero M; Lechuga-Sancho AM; Perdomo G; Garcia-Alloza M; Cozar-Castellano I. 2012. Increased Abeta production prompts the onset of glucose intolerance and insulin resistance.. In: . . MGI: J:186924
Jin JJ; Kim HD; Maxwell JA; Li L; Fukuchi K. 2008. Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease.. In: . . MGI: J:174833
Jo S; Yarishkin O; Hwang YJ; Chun YE; Park M; Woo DH; Bae JY; Kim T; Lee J; Chun H; Park HJ; Lee da Y; Hong J; Kim HY; Oh SJ; Park SJ; Lee H; Yoon BE; Kim Y; Jeong Y; Shim I; Bae YC; Cho J; Kowall NW; Ryu H; Hwang E; Kim D; Lee CJ. 2014. GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease.. In: . . MGI: J:227606
Johansson JU; Woodling NS; Wang Q; Panchal M; Liang X; Trueba-Saiz A; Brown HD; Mhatre SD; Loui T; Andreasson KI. 2015. Prostaglandin signaling suppresses beneficial microglial function in Alzheimer's disease models.. In: . . MGI: J:219607
Jones RS; Minogue AM; Fitzpatrick O; Lynch MA. 2015. Inhibition of JAK2 attenuates the increase in inflammatory markers in microglia from APP/PS1 mice.. In: . . MGI: J:232260
Joshi G; Chi Y; Huang Z; Wang Y. 2014. Abeta-induced Golgi fragmentation in Alzheimer's disease enhances Abeta production.. In: . . MGI: J:207368
Jung CK; Keppler K; Steinbach S; Blazquez-Llorca L; Herms J. 2015. Fibrillar amyloid plaque formation precedes microglial activation.. In: . . MGI: J:232972
Kagedal K; Kim WS; Appelqvist H; Chan S; Cheng D; Agholme L; Barnham K; McCann H; Halliday G; Garner B. 2010. Increased expression of the lysosomal cholesterol transporter NPC1 in Alzheimer's disease.. In: . . MGI: J:165464
Kajiwara Y; McKenzie A; Dorr N; Gama Sosa MA; Elder G; Schmeidler J; Dickstein DL; Bozdagi O; Zhang B; Buxbaum JD. 2016. The human-specific CASP4 gene product contributes to Alzheimer-related synaptic and behavioural deficits.. In: . . MGI: J:238562
Kamphuis W; Mamber C; Moeton M; Kooijman L; Sluijs JA; Jansen AH; Verveer M; de Groot LR; Smith VD; Rangarajan S; Rodriguez JJ; Orre M; Hol EM. 2012. GFAP isoforms in adult mouse brain with a focus on neurogenic astrocytes and reactive astrogliosis in mouse models of Alzheimer disease.. In: . . MGI: J:189978
Kamphuis W; Orre M; Kooijman L; Dahmen M; Hol EM. 2012. Differential cell proliferation in the cortex of the APPswePS1dE9 Alzheimer's disease mouse model.. In: . . MGI: J:181304
Kang JE; Lim MM; Bateman RJ; Lee JJ; Smyth LP; Cirrito JR; Fujiki N; Nishino S; Holtzman DM. 2009. Amyloid-{beta} Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle.. In: . . MGI: J:154074
Kanninen K; Heikkinen R; Malm T; Rolova T; Kuhmonen S; Leinonen H; Yla-Herttuala S; Tanila H; Levonen AL; Koistinaho M; Koistinaho J. 2009. Intrahippocampal injection of a lentiviral vector expressing Nrf2 improves spatial learning in a mouse model of Alzheimer's disease.. In: . . MGI: J:153226
Kanninen K; Malm TM; Jyrkkanen HK; Goldsteins G; Keksa-Goldsteine V; Tanila H; Yamamoto M; Yla-Herttuala S; Levonen AL; Koistinaho J. 2008. Nuclear factor erythroid 2-related factor 2 protects against beta amyloid.. In: . . MGI: J:142109
Kellner V; Menkes-Caspi N; Beker S; Stern EA. 2014. Amyloid-beta alters ongoing neuronal activity and excitability in the frontal cortex.. In: . . MGI: J:214853
Kemppainen S; Lindholm P; Galli E; Lahtinen HM; Koivisto H; Hamalainen E; Saarma M; Tanila H. 2015. Cerebral dopamine neurotrophic factor improves long-term memory in APP/PS1 transgenic mice modeling Alzheimer's disease as well as in wild-type mice.. In: . . MGI: J:227149
Kemppainen S; Rantamaki T; Jeronimo-Santos A; Lavasseur G; Autio H; Karpova N; Karkkainen E; Staven S; Miranda HV; Outeiro TF; Diogenes MJ; Laroche S; Davis S; Sebastiao AM; Castren E; Tanila H. 2012. Impaired TrkB receptor signaling contributes to memory impairment in APP/PS1 mice.. In: . . MGI: J:188313
Kim J; Castellano JM; Jiang H; Basak JM; Parsadanian M; Pham V; Mason SM; Paul SM; Holtzman DM. 2009. Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance.. In: . . MGI: J:155809
Kim JY; Kim DH; Kim JH; Lee D; Jeon HB; Kwon SJ; Kim SM; Yoo YJ; Lee EH; Choi SJ; Seo SW; Lee JI; Na DL; Yang YS; Oh W; Chang JW. 2012. Soluble intracellular adhesion molecule-1 secreted by human umbilical cord blood-derived mesenchymal stem cell reduces amyloid-beta plaques.. In: . . MGI: J:203613
Kim MJ; Chae SS; Koh YH; Lee SK; Jo SA. 2010. Glutamate carboxypeptidase II: an amyloid peptide-degrading enzyme with physiological function in the brain.. In: . . MGI: J:196634
Kim S; Lee D; Song JC; Cho SJ; Yun SM; Koh YH; Song J; Johnson GV; Jo C. 2014. NDP52 associates with phosphorylated tau in brains of an Alzheimer disease mouse model.. In: . . MGI: J:220278
Kim T; Vidal GS; Djurisic M; William CM; Birnbaum ME; Garcia KC; Hyman BT; Shatz CJ. 2013. Human LilrB2 is a beta-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer's model.. In: . . MGI: J:201126
Knafo S; Sanchez-Puelles C; Palomer E; Delgado I; Draffin JE; Mingo J; Wahle T; Kaleka K; Mou L; Pereda-Perez I; Klosi E; Faber EB; Chapman HM; Lozano-Montes L; Ortega-Molina A; Ordonez-Gutierrez L; Wandosell F; Vina J; Dotti CG; Hall RA; Pulido R; Gerges NZ; Chan AM; Spaller MR; Serrano M; Venero C; Esteban JA. 2016. PTEN recruitment controls synaptic and cognitive function in Alzheimer's models.. In: . . MGI: J:234430
Knafo S; Venero C; Merino-Serrais P; Fernaud-Espinosa I; Gonzalez-Soriano J; Ferrer I; Santpere G; DeFelipe J. 2009. Morphological alterations to neurons of the amygdala and impaired fear conditioning in a transgenic mouse model of Alzheimer's disease.. In: . . MGI: J:151904
Ko CY; Chang LH; Lee YC; Sterneck E; Cheng CP; Chen SH; Huang AM; Tseng JT; Wang JM. 2012. CCAAT/enhancer binding protein delta (CEBPD) elevating PTX3 expression inhibits macrophage-mediated phagocytosis of dying neuron cells.. In: . . MGI: J:188222
Ko CY; Chu YY; Narumiya S; Chi JY; Furuyashiki T; Aoki T; Wang SM; Chang WC; Wang JM. 2015. The CCAAT/enhancer-binding protein delta/miR135a/thrombospondin 1 axis mediates PGE2-induced angiogenesis in Alzheimer's disease.. In: . . MGI: J:221691
Ko CY; Wang WL; Wang SM; Chu YY; Chang WC; Wang JM. 2014. Glycogen synthase kinase-3beta-mediated CCAAT/enhancer-binding protein delta phosphorylation in astrocytes promotes migration and activation of microglia/macrophages.. In: . . MGI: J:211975
Koffie RM ; Meyer-Luehmann M ; Hashimoto T ; Adams KW ; Mielke ML ; Garcia-Alloza M ; Micheva KD ; Smith SJ ; Kim ML ; Lee VM ; Hyman BT ; Spires-Jones TL. 2009. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques.. In: . . MGI: J:146596
Koronyo-Hamaoui M; Ko MK; Koronyo Y; Azoulay D; Seksenyan A; Kunis G; Pham M; Bakhsheshian J; Rogeri P; Black KL; Farkas DL; Schwartz M. 2009. Attenuation of AD-like neuropathology by harnessing peripheral immune cells: local elevation of IL-10 and MMP-9.. In: . . MGI: J:156031
Krauthausen M; Kummer MP; Zimmermann J; Reyes-Irisarri E; Terwel D; Bulic B; Heneka MT; Muller M. 2015. CXCR3 promotes plaque formation and behavioral deficits in an Alzheimer's disease model.. In: . . MGI: J:219601
Kuchibhotla KV; Lattarulo CR; Hyman BT; Bacskai BJ. 2009. Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice.. In: . . MGI: J:145934
Kumar S; Rezaei-Ghaleh N; Terwel D; Thal DR; Richard M; Hoch M; Mc Donald JM; Wullner U; Glebov K; Heneka MT; Walsh DM; Zweckstetter M; Walter J. 2011. Extracellular phosphorylation of the amyloid beta-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease.. In: . . MGI: J:173179
Kummer MP; Hammerschmidt T; Martinez A; Terwel D; Eichele G; Witten A; Figura S; Stoll M; Schwartz S; Pape HC; Schultze JL; Weinshenker D; Heneka MT. 2014. Ear2 deletion causes early memory and learning deficits in APP/PS1 mice.. In: . . MGI: J:212542
Kummer MP; Hermes M; Delekarte A; Hammerschmidt T; Kumar S; Terwel D; Walter J; Pape HC; Konig S; Roeber S; Jessen F; Klockgether T; Korte M; Heneka MT. 2011. Nitration of tyrosine 10 critically enhances amyloid beta aggregation and plaque formation.. In: . . MGI: J:176667
Kummer MP; Vogl T; Axt D; Griep A; Vieira-Saecker A; Jessen F; Gelpi E; Roth J; Heneka MT. 2012. Mrp14 deficiency ameliorates amyloid beta burden by increasing microglial phagocytosis and modulation of amyloid precursor protein processing.. In: . . MGI: J:193190
Kuszczyk MA; Sanchez S; Pankiewicz J; Kim J; Duszczyk M; Guridi M; Asuni AA; Sullivan PM; Holtzman DM; Sadowski MJ. 2013. Blocking the Interaction between Apolipoprotein E and Abeta Reduces Intraneuronal Accumulation of Abeta and Inhibits Synaptic Degeneration.. In: . . MGI: J:195341
Kuwabara Y; Ishizeki M; Watamura N; Toba J; Yoshii A; Inoue T; Ohshima T. 2014. Impairments of long-term depression induction and motor coordination precede Abeta accumulation in the cerebellum of APPswe/PS1dE9 double transgenic mice.. In: . . MGI: J:214689
Lalonde R; Kim HD; Fukuchi K. 2004. Exploratory activity, anxiety, and motor coordination in bigenic APPswe + PS1/DeltaE9 mice.. In: . . MGI: J:93096
Lalonde R; Kim HD; Maxwell JA; Fukuchi K. 2005. Exploratory activity and spatial learning in 12-month-old APP(695)SWE/co+PS1/DeltaE9 mice with amyloid plaques.. In: . . MGI: J:104569
Lam V; Takechi R; Pallebage-Gamarallage MM; Galloway S; Mamo JC. 2011. Colocalisation of plasma derived apo B lipoproteins with cerebral proteoglycans in a transgenic-amyloid model of Alzheimer's disease.. In: . . MGI: J:170853
Lamoke F; Ripandelli G; Webster S; Montemari A; Maraschi A; Martin P; Marcus DM; Liou GI; Bartoli M. 2012. Loss of thioredoxin function in retinas of mice overexpressing amyloid beta.. In: . . MGI: J:186185
Laursen B; Mork A; Plath N; Kristiansen U; Bastlund JF. 2013. Cholinergic degeneration is associated with increased plaque deposition and cognitive impairment in APPswe/PS1dE9 mice.. In: . . MGI: J:197071
Ledo JH; Azevedo EP; Beckman D; Ribeiro FC; Santos LE; Razolli DS; Kincheski GC; Melo HM; Bellio M; Teixeira AL; Velloso LA; Foguel D; De Felice FG; Ferreira ST. 2016. Cross Talk Between Brain Innate Immunity and Serotonin Signaling Underlies Depressive-Like Behavior Induced by Alzheimer's Amyloid-beta Oligomers in Mice.. In: . . MGI: J:237190
Lee JE; Han PL. 2013. An update of animal models of Alzheimer disease with a reevaluation of plaque depositions.. In: . . MGI: J:202532
Lee SH; Kim Y; Kim HY; Kim YH; Kim MS; Kong JY; Lee MH; Kim DJ; Ahn YG. 2014. Aminostyrylbenzofuran directly reduces oligomeric amyloid-beta and reverses cognitive deficits in Alzheimer transgenic mice.. In: . . MGI: J:217233
Lefterov I; Fitz NF; Cronican AA; Fogg A; Lefterov P; Kodali R; Wetzel R; Koldamova R. 2010. Apolipoprotein A-I deficiency increases cerebral amyloid angiopathy and cognitive deficits in APP/PS1DeltaE9 mice.. In: . . MGI: J:166877
Lewis TL; Cao D; Lu H; Mans RA; Su YR; Jungbauer L; Linton MF; Fazio S; LaDu MJ; Li L. 2010. Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease.. In: . . MGI: J:167024
Li F; Wei G; Bai Y; Li Y; Huang F; Lin J; Hou Q; Deng R; Zhou JH; Zhang SX; Chen DF. 2015. MicroRNA-574 is involved in cognitive impairment in 5-month-old APP/PS1 mice through regulation of neuritin.. In: . . MGI: J:229409
Li HQ; Chen C; Dou Y; Wu HJ; Liu YJ; Lou HF; Zhang JM; Li XM; Wang H; Duan S. 2013. P2Y4 receptor-mediated pinocytosis contributes to amyloid beta-induced self-uptake by microglia.. In: . . MGI: J:205417
Li L; Wang XY; Gao FB; Wang L; Xia R; Li ZX; Xing W; Tang BS; Zeng Y; Zhou GF; Zhou HY; Liao WH. 2016. Magnetic resonance T2 relaxation time at 7 Tesla associated with amyloid beta pathology and age in a double-transgenic mouse model of Alzheimer's disease.. In: . . MGI: J:228752
Li T; Braunstein KE; Zhang J; Lau A; Sibener L; Deeble C; Wong PC. 2016. The neuritic plaque facilitates pathological conversion of tau in an Alzheimer's disease mouse model.. In: . . MGI: J:240784
Li T; Wen H; Brayton C; Laird FM; Ma G; Peng S; Placanica L; Wu TC; Crain BJ; Price DL; Eberhart CG; Wong PC. 2007. Moderate reduction of gamma-secretase attenuates amyloid burden and limits mechanism-based liabilities.. In: . . MGI: J:125592
Li Y; Xu M; Ding X; Yan C; Song Z; Chen L; Huang X; Wang X; Jian Y; Tang G; Tang C; Di Y; Mu S; Liu X; Liu K; Li T; Wang Y; Miao L; Guo W; Hao X; Yang C. 2016. Protein kinase C controls lysosome biogenesis independently of mTORC1.. In: . . MGI: J:238560
Lian H; Litvinchuk A; Chiang AC; Aithmitti N; Jankowsky JL; Zheng H. 2016. Astrocyte-Microglia Cross Talk through Complement Activation Modulates Amyloid Pathology in Mouse Models of Alzheimer's Disease.. In: . . MGI: J:228864
Liang B; Duan BY; Zhou XP; Gong JX; Luo ZG. 2010. Calpain activation promotes BACE1 expression, amyloid precursor protein processing, and amyloid plaque formation in a transgenic mouse model of Alzheimer disease.. In: . . MGI: J:166179
Liang X; Wang Q; Hand T; Wu L; Breyer RM; Montine TJ; Andreasson K. 2005. Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease.. In: . . MGI: J:102728
Liebmann T; Renier N; Bettayeb K; Greengard P; Tessier-Lavigne M; Flajolet M. 2016. Three-Dimensional Study of Alzheimer's Disease Hallmarks Using the iDISCO Clearing Method.. In: . . MGI: J:238659
Lim JE; Kou J; Song M; Pattanayak A; Jin J; Lalonde R; Fukuchi K. 2011. MyD88 deficiency ameliorates beta-amyloidosis in an animal model of Alzheimer's disease.. In: . . MGI: J:176316
Lim JE; Song M; Jin J; Kou J; Pattanayak A; Lalonde R; Fukuchi K. 2012. The effects of MyD88 deficiency on exploratory activity, anxiety, motor coordination, and spatial learning in C57BL/6 and APPswe/PS1dE9 mice.. In: . . MGI: J:180681
Liu B; Le KX; Park MA; Wang S; Belanger AP; Dubey S; Frost JL; Holton P; Reiser V; Jones PA; Trigg W; Di Carli MF; Lemere CA. 2015. In Vivo Detection of Age- and Disease-Related Increases in Neuroinflammation by 18F-GE180 TSPO MicroPET Imaging in Wild-Type and Alzheimer's Transgenic Mice.. In: . . MGI: J:227839
Liu CC; Hu J; Zhao N; Wang J; Wang N; Cirrito JR; Kanekiyo T; Holtzman DM; Bu G. 2017. Astrocytic LRP1 Mediates Brain Abeta Clearance and Impacts Amyloid Deposition.. In: . . MGI: J:240679
Liu CC; Tsai CW; Deak F; Rogers J; Penuliar M; Sung YM; Maher JN; Fu Y; Li X; Xu H; Estus S; Hoe HS; Fryer JD; Kanekiyo T; Bu G. 2014. Deficiency in LRP6-mediated Wnt signaling contributes to synaptic abnormalities and amyloid pathology in Alzheimer's disease.. In: . . MGI: J:217895
Liu HL; Zhao G; Zhang H; Shi LD. 2013. Long-term treadmill exercise inhibits the progression of Alzheimer's disease-like neuropathology in the hippocampus of APP/PS1 transgenic mice.. In: . . MGI: J:202342
Liu MY; Wang S; Yao WF; Zhang ZJ; Zhong X; Sha L; He M; Zheng ZH; Wei MJ. 2014. Memantine improves spatial learning and memory impairments by regulating NGF signaling in APP/PS1 transgenic mice.. In: . . MGI: J:213211
Liu R; Li JZ; Song JK; Zhou D; Huang C; Bai XY; Xie T; Zhang X; Li YJ; Wu CX; Zhang L; Li L; Zhang TT; Du GH. 2014. Pinocembrin improves cognition and protects the neurovascular unit in Alzheimer related deficits.. In: . . MGI: J:213884
Liu RM; van Groen T; Katre A; Cao D; Kadisha I; Ballinger C; Wang L; Carroll SL; Li L. 2011. Knockout of plasminogen activator inhibitor 1 gene reduces amyloid beta peptide burden in a mouse model of Alzheimer's disease.. In: . . MGI: J:173735
Liu S; Liu Y; Hao W; Wolf L; Kiliaan AJ; Penke B; Rube CE; Walter J; Heneka MT; Hartmann T; Menger MD; Fassbender K. 2012. TLR2 is a primary receptor for Alzheimer's amyloid beta peptide to trigger neuroinflammatory activation.. In: . . MGI: J:180762
Lok K; Zhao H; Shen H; Wang Z; Gao X; Zhao W; Yin M. 2013. Characterization of the APP/PS1 mouse model of Alzheimer's disease in senescence accelerated background.. In: . . MGI: J:207860
Lourenco MV; Clarke JR; Frozza RL; Bomfim TR; Forny-Germano L; Batista AF; Sathler LB; Brito-Moreira J; Amaral OB; Silva CA; Freitas-Correa L; Espirito-Santo S; Campello-Costa P; Houzel JC; Klein WL; Holscher C; Carvalheira JB; Silva AM; Velloso LA; Munoz DP; Ferreira ST; De Felice FG. 2013. TNF-alpha mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's beta-amyloid oligomers in mice and monkeys.. In: . . MGI: J:206139
Lutzenberger M; Burwinkel M; Riemer C; Bode V; Baier M. 2015. Ablation of CCAAT/Enhancer-Binding Protein Delta (C/EBPD): Increased Plaque Burden in a Murine Alzheimer's Disease Model.. In: . . MGI: J:238606
Ma T; Du X; Pick JE; Sui G; Brownlee M; Klann E. 2012. Glucagon-like peptide-1 cleavage product GLP-1(9-36) amide rescues synaptic plasticity and memory deficits in Alzheimer's disease model mice.. In: . . MGI: J:190933
Ma T; Trinh MA; Wexler AJ; Bourbon C; Gatti E; Pierre P; Cavener DR; Klann E. 2013. Suppression of eIF2alpha kinases alleviates Alzheimer's disease-related plasticity and memory deficits.. In: . . MGI: J:203865
Macauley SL; Stanley M; Caesar EE; Yamada SA; Raichle ME; Perez R; Mahan TE; Sutphen CL; Holtzman DM. 2015. Hyperglycemia modulates extracellular amyloid-beta concentrations and neuronal activity in vivo.. In: . . MGI: J:222966
Machova E; Jakubik J; Michal P; Oksman M; Iivonen H; Tanila H; Dolezal V. 2008. Impairment of muscarinic transmission in transgenic APPswe/PS1dE9 mice.. In: . . MGI: J:135055
Machova E; Rudajev V; Smyckova H; Koivisto H; Tanila H; Dolezal V. 2010. Functional cholinergic damage develops with amyloid accumulation in young adult APPswe/PS1dE9 transgenic mice.. In: . . MGI: J:159939
Maingret V; Barthet G; Deforges S; Jiang N; Mulle C; Amedee T. 2017. PGE2-EP3 signaling pathway impairs hippocampal presynaptic long-term plasticity in a mouse model of Alzheimer's disease.. In: . . MGI: J:239753
Majumder P; Roy K; Singh BK; Jana NR; Mukhopadhyay D. 2017. Cellular levels of Grb2 and cytoskeleton stability are correlated in a neurodegenerative scenario.. In: . . MGI: J:242308
Malm TM; Iivonen H; Goldsteins G; Keksa-Goldsteine V; Ahtoniemi T; Kanninen K; Salminen A; Auriola S; Van Groen T; Tanila H; Koistinaho J. 2007. Pyrrolidine dithiocarbamate activates Akt and improves spatial learning in APP/PS1 mice without affecting beta-amyloid burden.. In: . . MGI: J:119404
Manocha GD; Floden AM; Rausch K; Kulas JA; McGregor BA; Rojanathammanee L; Puig KR; Puig KL; Karki S; Nichols MR; Darland DC; Porter JE; Combs CK. 2016. APP Regulates Microglial Phenotype in a Mouse Model of Alzheimer's Disease.. In: . . MGI: J:234769
Mao YF; Guo Z; Zheng T; Jiang Y; Yan Y; Yin X; Chen Y; Zhang B. 2016. Intranasal insulin alleviates cognitive deficits and amyloid pathology in young adult APPswe/PS1dE9 mice.. In: . . MGI: J:236533
Martin E; Boucher C; Fontaine B; Delarasse C. 2017. Distinct inflammatory phenotypes of microglia and monocyte-derived macrophages in Alzheimer's disease models: effects of aging and amyloid pathology.. In: . . MGI: J:238754
Matsuda S; Giliberto L; Matsuda Y; McGowan EM; D'Adamio L. 2008. BRI2 inhibits amyloid beta-peptide precursor protein processing by interfering with the docking of secretases to the substrate.. In: . . MGI: J:138796
Matsumoto Y; Niimi N; Kohyama K. 2013. Development of a new DNA vaccine for Alzheimer disease targeting a wide range of abeta species and amyloidogenic peptides.. In: . . MGI: J:206020
Mazzitelli S; Xu P; Ferrer I; Davis RJ; Tournier C. 2011. The Loss of c-Jun N-Terminal Protein Kinase Activity Prevents the Amyloidogenic Cleavage of Amyloid Precursor Protein and the Formation of Amyloid Plaques In Vivo.. In: . . MGI: J:178060
McClean PL; Holscher C. 2014. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.. In: . . MGI: J:214503
McClean PL; Jalewa J; Holscher C. 2015. Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice.. In: . . MGI: J:227289
McManus RM; Higgins SC; Mills KH; Lynch MA. 2014. Respiratory infection promotes T cell infiltration and amyloid-beta deposition in APP/PS1 mice.. In: . . MGI: J:211974
Meckler X; Roseman J; Das P; Cheng H; Pei S; Keat M; Kassarjian B; Golde TE; Parent AT; Thinakaran G. 2010. Reduced Alzheimer's disease ss-amyloid deposition in transgenic mice expressing S-palmitoylation-deficient APH1aL and nicastrin.. In: . . MGI: J:166746
Megill A; Tran T; Eldred K; Lee NJ; Wong PC; Hoe HS; Kirkwood A; Lee HK. 2015. Defective Age-Dependent Metaplasticity in a Mouse Model of Alzheimer's Disease.. In: . . MGI: J:226019
Mei X; Ezan P; Giaume C; Koulakoff A. 2010. Astroglial connexin immunoreactivity is specifically altered at beta-amyloid plaques in beta-amyloid precursor protein/presenilin1 mice.. In: . . MGI: J:169720
Mellott TJ; Pender SM; Burke RM; Langley EA; Blusztajn JK. 2014. IGF2 ameliorates amyloidosis, increases cholinergic marker expression and raises BMP9 and neurotrophin levels in the hippocampus of the APPswePS1dE9 Alzheimer's disease model mice.. In: . . MGI: J:215221
Melnikova T; Savonenko A; Wang Q; Liang X; Hand T; Wu L; Kaufmann WE; Vehmas A; Andreasson KI. 2006. Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern.. In: . . MGI: J:111748
Meyer-Luehmann M; Mielke M; Spires-Jones TL; Stoothoff W; Jones P; Bacskai BJ; Hyman BT. 2009. A reporter of local dendritic translocation shows plaque- related loss of neural system function in APP-transgenic mice.. In: . . MGI: J:153880
Meyer-Luehmann M; Spires-Jones TL; Prada C; Garcia-Alloza M; de Calignon A; Rozkalne A; Koenigsknecht-Talboo J; Holtzman DM; Bacskai BJ; Hyman BT. 2008. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease.. In: . . MGI: J:132628
Michaud JP; Bellavance MA; Prefontaine P; Rivest S. 2013. Real-time in vivo imaging reveals the ability of monocytes to clear vascular amyloid beta.. In: . . MGI: J:205530
Michaud JP; Halle M; Lampron A; Theriault P; Prefontaine P; Filali M; Tribout-Jover P; Lanteigne AM; Jodoin R; Cluff C; Brichard V; Palmantier R; Pilorget A; Larocque D; Rivest S. 2013. Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer's disease-related pathology.. In: . . MGI: J:193688
Minkeviciene R; Ihalainen J; Malm T; Matilainen O; Keksa-Goldsteine V; Goldsteins G; Iivonen H; Leguit N; Glennon J; Koistinaho J; Banerjee P; Tanila H. 2008. Age-related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild-type mice.. In: . . MGI: J:134481
Minkeviciene R; Rheims S; Dobszay MB; Zilberter M; Hartikainen J; Fulop L; Penke B; Zilberter Y; Harkany T; Pitkanen A; Tanila H. 2009. Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy.. In: . . MGI: J:147045
Minogue AM; Jones RS; Kelly RJ; McDonald CL; Connor TJ; Lynch MA. 2014. Age-associated dysregulation of microglial activation is coupled with enhanced blood-brain barrier permeability and pathology in APP/PS1 mice.. In: . . MGI: J:213885
Montgomery KS; Simmons RK; Edwards G 3rd; Nicolle MM; Gluck MA; Myers CE; Bizon JL. 2011. Novel age-dependent learning deficits in a mouse model of Alzheimer's disease: Implications for translational research.. In: . . MGI: J:173732
Mori T; Koyama N; Guillot-Sestier MV; Tan J; Town T. 2013. Ferulic acid is a nutraceutical beta-secretase modulator that improves behavioral impairment and alzheimer-like pathology in transgenic mice.. In: . . MGI: J:197205
Mori T; Koyama N; Segawa T; Maeda M; Maruyama N; Kinoshita N; Hou H; Tan J; Town T. 2014. Methylene blue modulates beta-secretase, reverses cerebral amyloidosis, and improves cognition in transgenic mice.. In: . . MGI: J:217762
Mori T; Rezai-Zadeh K; Koyama N; Arendash GW; Yamaguchi H; Kakuda N; Horikoshi-Sakuraba Y; Tan J; Town T. 2012. Tannic acid is a natural beta-secretase inhibitor that prevents cognitive impairment and mitigates Alzheimer-like pathology in transgenic mice.. In: . . MGI: J:182430
Moskovitz J; Maiti P; Lopes DH; Oien DB; Attar A; Liu T; Mittal S; Hayes J; Bitan G. 2011. Induction of Methionine-Sulfoxide Reductases Protects Neurons from Amyloid beta-Protein Insults in Vitro and in Vivo.. In: . . MGI: J:178628
Nabuurs RJ; Rutgers KS; Welling MM; Metaxas A; de Backer ME; Rotman M; Bacskai BJ; van Buchem MA; van der Maarel SM; van der Weerd L. 2012. In vivo detection of amyloid-beta deposits using heavy chain antibody fragments in a transgenic mouse model for Alzheimer's disease.. In: . . MGI: J:187847
Ni Y; Zhao X; Bao G; Zou L; Teng L; Wang Z; Song M; Xiong J; Bai Y; Pei G. 2006. Activation of beta2-adrenergic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation.. In: . . MGI: J:117739
Ning A; Cui J; To E; Ashe KH; Matsubara J. 2008. Amyloid-beta deposits lead to retinal degeneration in a mouse model of Alzheimer disease.. In: . . MGI: J:141764
O'Leary TP; Brown RE. 2009. Visuo-spatial learning and memory deficits on the Barnes maze in the 16-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.. In: . . MGI: J:148386
O'Neil JN; Mouton PR; Tizabi Y; Ottinger MA; Lei DL; Ingram DK; Manaye KF. 2007. Catecholaminergic neuronal loss in locus coeruleus of aged female dtg APP/PS1 mice.. In: . . MGI: J:129903
Oh ES; Savonenko AV; King JF; Fangmark Tucker SM; Rudow GL; Xu G; Borchelt DR; Troncoso JC. 2009. Amyloid precursor protein increases cortical neuron size in transgenic mice.. In: . . MGI: J:152955
Ohno M; Hiraoka Y; Lichtenthaler SF; Nishi K; Saijo S; Matsuoka T; Tomimoto H; Araki W; Takahashi R; Kita T; Kimura T; Nishi E. 2014. Nardilysin prevents amyloid plaque formation by enhancing alpha-secretase activity in an Alzheimer's disease mouse model.. In: . . MGI: J:211980
Ordonez-Gutierrez L; Fernandez-Perez I; Herrera JL; Anton M; Benito-Cuesta I; Wandosell F. 2016. AbetaPP/PS1 Transgenic Mice Show Sex Differences in the Cerebellum Associated with Aging.. In: . . MGI: J:234618
Ordonez-Gutierrez L; Torres JM; Gavin R; Anton M; Arroba-Espinosa AI; Espinosa JC; Vergara C; Del Rio JA; Wandosell F. 2013. Cellular prion protein modulates beta-amyloid deposition in aged APP/PS1 transgenic mice.. In: . . MGI: J:211720
Orre M; Kamphuis W; Osborn LM; Jansen AH; Kooijman L; Bossers K; Hol EM. 2014. Isolation of glia from Alzheimer's mice reveals inflammation and dysfunction.. In: . . MGI: J:218071
Ostapchenko VG; Beraldo FH; Guimaraes AL; Mishra S; Guzman M; Fan J; Martins VR; Prado VF; Prado MA. 2013. Increased prion protein processing and expression of metabotropic glutamate receptor 1 in a mouse model of Alzheimer's disease.. In: . . MGI: J:202644
Ostapchenko VG; Chen M; Guzman MS; Xie YF; Lavine N; Fan J; Beraldo FH; Martyn AC; Belrose JC; Mori Y; MacDonald JF; Prado VF; Prado MA; Jackson MF. 2015. The Transient Receptor Potential Melastatin 2 (TRPM2) Channel Contributes to beta-Amyloid Oligomer-Related Neurotoxicity and Memory Impairment.. In: . . MGI: J:227849
Pan X; Nasaruddin MB; Elliott CT; McGuinness B; Passmore AP; Kehoe PG; Holscher C; McClean PL; Graham SF; Green BD. 2016. Alzheimer's disease-like pathology has transient effects on the brain and blood metabolome.. In: . . MGI: J:234515
Park JH; Gimbel DA; GrandPre T; Lee JK; Kim JE; Li W; Lee DH; Strittmatter SM. 2006. Alzheimer precursor protein interaction with the Nogo-66 receptor reduces amyloid-beta plaque deposition.. In: . . MGI: J:105196
Park JH; Widi GA; Gimbel DA; Harel NY; Lee DH; Strittmatter SM. 2006. Subcutaneous Nogo receptor removes brain amyloid-beta and improves spatial memory in Alzheimer's transgenic mice.. In: . . MGI: J:116775
Parthsarathy V; Holscher C. 2013. Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model.. In: . . MGI: J:200176
Parthsarathy V; McClean PL; Holscher C; Taylor M; Tinker C; Jones G; Kolosov O; Salvati E; Gregori M; Masserini M; Allsop D. 2013. A novel retro-inverso peptide inhibitor reduces amyloid deposition, oxidation and inflammation and stimulates neurogenesis in the APPswe/PS1DeltaE9 mouse model of Alzheimer's disease.. In: . . MGI: J:195789
Pedros I; Petrov D; Allgaier M; Sureda F; Barroso E; Beas-Zarate C; Auladell C; Pallas M; Vazquez-Carrera M; Casadesus G; Folch J; Camins A. 2014. Early alterations in energy metabolism in the hippocampus of APPswe/PS1dE9 mouse model of Alzheimer's disease.. In: . . MGI: J:217927
Peng W; Achariyar TM; Li B; Liao Y; Mestre H; Hitomi E; Regan S; Kasper T; Peng S; Ding F; Benveniste H; Nedergaard M; Deane R. 2016. Suppression of glymphatic fluid transport in a mouse model of Alzheimer's disease.. In: . . MGI: J:231726
Petrov D; Pedros I; Artiach G; Sureda FX; Barroso E; Pallas M; Casadesus G; Beas-Zarate C; Carro E; Ferrer I; Vazquez-Carrera M; Folch J; Camins A. 2015. High-fat diet-induced deregulation of hippocampal insulin signaling and mitochondrial homeostasis deficiences contribute to Alzheimer disease pathology in rodents.. In: . . MGI: J:233933
Phillips M; Boman E; Osterman H; Willhite D; Laska M. 2011. Olfactory and visuospatial learning and memory performance in two strains of Alzheimer's disease model mice-a longitudinal study.. In: . . MGI: J:172426
Pietropaolo S; Delage P; Lebreton F; Crusio WE; Cho YH. 2012. Early development of social deficits in APP and APP-PS1 mice.. In: . . MGI: J:188187
Pihlaja R; Koistinaho J; Malm T; Sikkila H; Vainio S; Koistinaho M. 2008. Transplanted astrocytes internalize deposited beta-amyloid peptides in a transgenic mouse model of Alzheimer's disease.. In: . . MGI: J:156291
Pinto M; Pickrell AM; Fukui H; Moraes CT. 2013. Mitochondrial DNA damage in a mouse model of Alzheimer's disease decreases amyloid beta plaque formation.. In: . . MGI: J:211726
Poirier R; Fernandez AM; Torres-Aleman I; Metzger F. 2012. Early brain amyloidosis in APP/PS1 mice with serum insulin-like growth factor-I deficiency.. In: . . MGI: J:182316
Puig KL; Kulas JA; Franklin W; Rakoczy SG; Taglialatela G; Brown-Borg HM; Combs CK. 2016. The Ames dwarf mutation attenuates Alzheimer's disease phenotype of APP/PS1 mice.. In: . . MGI: J:234665
Ramos-Rodriguez JJ; Molina-Gil S; Rey-Brea R; Berrocoso E; Garcia-Alloza M. 2013. Specific serotonergic denervation affects tau pathology and cognition without altering senile plaques deposition in APP/PS1 mice.. In: . . MGI: J:209785
Rantamaki T; Kemppainen S; Autio H; Staven S; Koivisto H; Kojima M; Antila H; Miettinen PO; Karkkainen E; Karpova N; Vesa L; Lindemann L; Hoener MC; Tanila H; Castren E. 2013. The impact of Bdnf gene deficiency to the memory impairment and brain pathology of APPswe/PS1dE9 mouse model of Alzheimer's disease.. In: . . MGI: J:204296
Rao SK; Ross JM; Harrison FE; Bernardo A; Reiserer RS; Reiserer RS; Mobley JA; McDonald MP. 2015. Differential proteomic and behavioral effects of long-term voluntary exercise in wild-type and APP-overexpressing transgenics.. In: . . MGI: J:223353
Rauch SM; Huen K; Miller MC; Chaudry H; Lau M; Sanes JR; Johanson CE; Stopa EG; Burgess RW. 2011. Changes in brain beta-amyloid deposition and aquaporin 4 levels in response to altered agrin expression in mice.. In: . . MGI: J:220073
Reed-Geaghan EG; Reed QW; Cramer PE; Landreth GE. 2010. Deletion of CD14 attenuates Alzheimer's disease pathology by influencing the brain's inflammatory milieu.. In: . . MGI: J:166445
Rey NL; Jardanhazi-Kurutz D; Terwel D; Kummer MP; Jourdan F; Didier A; Heneka MT. 2012. Locus coeruleus degeneration exacerbates olfactory deficits in APP/PS1 transgenic mice.. In: . . MGI: J:188223
Richner M; Bach G; West MJ. 2009. Over expression of amyloid beta-protein reduces the number of neurons in the striatum of APPswe/PS1DeltaE9.. In: . . MGI: J:145530
Roh JH; Huang Y; Bero AW; Kasten T; Stewart FR; Bateman RJ; Holtzman DM. 2012. Disruption of the Sleep-Wake Cycle and Diurnal Fluctuation of beta-Amyloid in Mice with Alzheimer's Disease Pathology.. In: . . MGI: J:188120
Rolova T; Puli L; Magga J; Dhungana H; Kanninen K; Wojciehowski S; Salminen A; Tanila H; Koistinaho J; Malm T. 2014. Complex regulation of acute and chronic neuroinflammatory responses in mouse models deficient for nuclear factor kappa B p50 subunit.. In: . . MGI: J:211484
Rosen RF; Tomidokoro Y; Farberg AS; Dooyema J; Ciliax B; Preuss TM; Neubert TA; Ghiso JA; LeVine H 3rd; Walker LC. 2016. Comparative pathobiology of beta-amyloid and the unique susceptibility of humans to Alzheimer's disease.. In: . . MGI: J:239036
Roy DS; Arons A; Mitchell TI; Pignatelli M; Ryan TJ; Tonegawa S. 2016. Memory retrieval by activating engram cells in mouse models of early Alzheimer's disease.. In: . . MGI: J:232713
Rudinskiy N; Hawkes JM; Betensky RA; Eguchi M; Yamaguchi S; Spires-Jones TL; Hyman BT. 2012. Orchestrated experience-driven Arc responses are disrupted in a mouse model of Alzheimer's disease.. In: . . MGI: J:191574
Saiz-Sanchez D; De La Rosa-Prieto C; Ubeda-Banon I; Martinez-Marcos A. 2013. Interneurons and Beta-Amyloid in the Olfactory Bulb, Anterior Olfactory Nucleus and Olfactory Tubercle in APPxPS1 Transgenic Mice Model of Alzheimer's Disease.. In: . . MGI: J:199785
Sakae N; Liu CC; Shinohara M; Frisch-Daiello J; Ma L; Yamazaki Y; Tachibana M; Younkin L; Kurti A; Carrasquillo MM; Zou F; Sevlever D; Bisceglio G; Gan M; Fol R; Knight P; Wang M; Han X; Fryer JD; Fitzgerald ML; Ohyagi Y; Younkin SG; Bu G; Kanekiyo T. 2016. ABCA7 Deficiency Accelerates Amyloid-beta Generation and Alzheimer's Neuronal Pathology.. In: . . MGI: J:231748
Saleem S; Biswas SC. 2017. Tribbles Pseudokinase 3 Induces Both Apoptosis and Autophagy in Amyloid-beta-induced Neuronal Death.. In: . . MGI: J:240888
Sashindranath M; Samson AL; Downes CE; Crack PJ; Lawrence AJ; Li QX; Ng AQ; Jones NC; Farrugia JJ; Abdella E; Vassalli JD; Madani R; Medcalf RL. 2011. Compartment- and context-specific changes in tissue-type plasminogen activator (tPA) activity following brain injury and pharmacological stimulation.. In: . . MGI: J:173193
Savonenko AV; Melnikova T; Wang Y; Ravert H; Gao Y; Koppel J; Lee D; Pletnikova O; Cho E; Sayyida N; Hiatt A; Troncoso J; Davies P; Dannals RF; Pomper MG; Horti AG. 2015. Cannabinoid CB2 Receptors in a Mouse Model of Abeta Amyloidosis: Immunohistochemical Analysis and Suitability as a PET Biomarker of Neuroinflammation.. In: . . MGI: J:233803
Schmole AC; Lundt R; Ternes S; Albayram O; Ulas T; Schultze JL; Bano D; Nicotera P; Alferink J; Zimmer A. 2015. Cannabinoid receptor 2 deficiency results in reduced neuroinflammation in an Alzheimer's disease mouse model.. In: . . MGI: J:219515
Scott L; Feng J; Kiss T; Needle E; Atchison K; Kawabe TT; Milici AJ; Hajos-Korcsok E; Riddell D; Hajos M. 2012. Age-dependent disruption in hippocampal theta oscillation in amyloid-beta overproducing transgenic mice.. In: . . MGI: J:188311
Sehgal N; Gupta A; Valli RK; Joshi SD; Mills JT; Hamel E; Khanna P; Jain SC; Thakur SS; Ravindranath V. 2012. Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver.. In: . . MGI: J:182629
Seo JS; Lee KW; Kim TK; Baek IS; Im JY; Han PL. 2011. Behavioral stress causes mitochondrial dysfunction via ABAD up-regulation and aggravates plaque pathology in the brain of a mouse model of Alzheimer disease.. In: . . MGI: J:172085
Sepulveda-Falla D; Barrera-Ocampo A; Hagel C; Korwitz A; Vinueza-Veloz MF; Zhou K; Schonewille M; Zhou H; Velazquez-Perez L; Rodriguez-Labrada R; Villegas A; Ferrer I; Lopera F; Langer T; De Zeeuw CI; Glatzel M. 2014. Familial Alzheimer's disease-associated presenilin-1 alters cerebellar activity and calcium homeostasis.. In: . . MGI: J:209633
Shaftel SS; Kyrkanides S; Olschowka JA; Miller JN; Johnson RE; O'Banion MK. 2007. Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology.. In: . . MGI: J:122022
Sharoar MG; Shi Q; Ge Y; He W; Hu X; Perry G; Zhu X; Yan R. 2016. Dysfunctional tubular endoplasmic reticulum constitutes a pathological feature of Alzheimer's disease.. In: . . MGI: J:240007
Shemer I; Holmgren C; Min R; Fulop L; Zilberter M; Sousa KM; Farkas T; Hartig W; Penke B; Burnashev N; Tanila H; Zilberter Y; Harkany T. 2006. Non-fibrillar beta-amyloid abates spike-timing-dependent synaptic potentiation at excitatory synapses in layer 2/3 of the neocortex by targeting postsynaptic AMPA receptors.. In: . . MGI: J:108064
Shen X; Chen J; Li J; Kofler J; Herrup K. 2016. Neurons in Vulnerable Regions of the Alzheimer's Disease Brain Display Reduced ATM Signaling.. In: . . MGI: J:240236
Sheng JG; Price DL; Koliatsos VE. 2002. Disruption of corticocortical connections ameliorates amyloid burden in terminal fields in a transgenic model of Abeta amyloidosis.. In: . . MGI: J:134697
Shi Q; Prior M; He W; Tang X; Hu X; Yan R. 2009. Reduced amyloid deposition in mice overexpressing RTN3 is adversely affected by preformed dystrophic neurites.. In: . . MGI: J:151798
Shu L; Sun W; Li L; Xu Z; Lin L; Xie P; Shen H; Huang L; Xu Q; Jin P; Li X. 2016. Genome-wide alteration of 5-hydroxymenthylcytosine in a mouse model of Alzheimer's disease.. In: . . MGI: J:236050
Sierksma AS; Prickaerts J; Chouliaras L; Rostamian S; Delbroek L; Rutten BP; Steinbusch HW; van den Hove DL. 2013. Behavioral and neurobiological effects of prenatal stress exposure in male and female APPswe/PS1dE9 mice.. In: . . MGI: J:191600
Sierksma AS; Rutten K; Sydlik S; Rostamian S; Steinbusch HW; van den Hove DL; Prickaerts J. 2013. Chronic phosphodiesterase type 2 inhibition improves memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease.. In: . . MGI: J:192673
Song S; Lee H; Kam TI; Tai ML; Lee JY; Noh JY; Shim SM; Seo SJ; Kong YY; Nakagawa T; Chung CW; Choi DY; Oubrahim H; Jung YK. 2008. E2-25K/Hip-2 regulates caspase-12 in ER stress-mediated Abeta neurotoxicity.. In: . . MGI: J:138978
Soto I; Grabowska WA; Onos KD; Graham LC; Jackson HM; Simeone SN; Howell GR. 2016. Meox2 haploinsufficiency increases neuronal cell loss in a mouse model of Alzheimer's disease.. In: . . MGI: J:235009
Sotthibundhu A; Li QX; Thangnipon W; Coulson EJ. 2009. Abeta(1-42) stimulates adult SVZ neurogenesis through the p75 neurotrophin receptor.. In: . . MGI: J:155160
Stoltenberg M; Bush AI; Bach G; Smidt K; Larsen A; Rungby J; Lund S; Doering P; Danscher G. 2007. Amyloid plaques arise from zinc-enriched cortical layers in APP/PS1 transgenic mice and are paradoxically enlarged with dietary zinc deficiency.. In: . . MGI: J:130788
Stover KR; Brown RE. 2012. Age-related changes in visual acuity, learning and memory in the APPswe/PS1dE9 mouse model of Alzheimer's disease.. In: . . MGI: J:181681
Stukas S; Freeman L; Lee M; Wilkinson A; Ossoli A; Vaisman B; Demosky S; Chan J; Hirsch-Reinshagen V; Remaley AT; Wellington CL. 2014. LCAT deficiency does not impair amyloid metabolism in APP/PS1 mice.. In: . . MGI: J:214980
Stukas S; May S; Wilkinson A; Chan J; Donkin J; Wellington CL. 2012. The LXR agonist GW3965 increases apoA-I protein levels in the central nervous system independent of ABCA1.. In: . . MGI: J:182371
Su D; Zhao Y; Xu H; Wang B; Chen X; Chen J; Wang X. 2012. Isoflurane exposure during mid-adulthood attenuates age-related spatial memory impairment in APP/PS1 transgenic mice.. In: . . MGI: J:195580
Sullivan SE; Dillon GM; Sullivan JM; Ho A. 2014. Mint proteins are required for synaptic activity-dependent amyloid precursor protein (APP) trafficking and amyloid beta generation.. In: . . MGI: J:215945
Sun S; Zhang H; Liu J; Popugaeva E; Xu NJ; Feske S; White CL 3rd; Bezprozvanny I. 2014. Reduced synaptic STIM2 expression and impaired store-operated calcium entry cause destabilization of mature spines in mutant presenilin mice.. In: . . MGI: J:213159
Sun X; Wu Y; Gu M; Liu Z; Ma Y; Li J; Zhang Y. 2014. Selective filtering defect at the axon initial segment in Alzheimer's disease mouse models.. In: . . MGI: J:216470
Sun X; Wu Y; Gu M; Zhang Y. 2014. miR-342-5p decreases ankyrin G levels in Alzheimer's disease transgenic mouse models.. In: . . MGI: J:208793
Sung HY; Choi EN; Lyu D; Mook-Jung I; Ahn JH. 2014. Amyloid beta-mediated epigenetic alteration of insulin-like growth factor binding protein 3 controls cell survival in Alzheimer's disease.. In: . . MGI: J:216819
Takata K; Kitamura Y; Saeki M; Terada M; Kagitani S; Kitamura R; Fujikawa Y; Maelicke A; Tomimoto H; Taniguchi T; Shimohama S. 2010. Galantamine-induced amyloid-{beta} clearance mediated via stimulation of microglial nicotinic acetylcholine receptors.. In: . . MGI: J:167587
Takeda S; Hashimoto T; Roe AD; Hori Y; Spires-Jones TL; Hyman BT. 2013. Brain interstitial oligomeric amyloid beta increases with age and is resistant to clearance from brain in a mouse model of Alzheimer's disease.. In: . . MGI: J:203564
Tamayev R; Matsuda S; Giliberto L; Arancio O; D'Adamio L. 2011. APP heterozygosity averts memory deficit in knockin mice expressing the Danish dementia BRI2 mutant.. In: . . MGI: J:173362
Tang M; Shi S; Guo Y; Xu W; Wang L; Chen Y; Wang Z; Qiao Z. 2014. GSK-3/CREB pathway involved in the gx-50's effect on Alzheimer's disease.. In: . . MGI: J:215368
Tang Y; Peng Y; Liu J; Shi L; Wang Y; Long J; Liu J. 2015. Early inflammation-associated factors blunt sterol regulatory element-binding proteins-1-mediated lipogenesis in high-fat diet-fed APP /PSEN1dE9 mouse model of Alzheimer's disease.. In: . . MGI: J:231345
Tavares E; Antequera D; Lopez-Gonzalez I; Ferrer I; Minano FJ; Carro E. 2016. Potential Role of Aminoprocalcitonin in the Pathogenesis of Alzheimer Disease.. In: . . MGI: J:235609
Taylor JM; Minter MR; Newman AG; Zhang M; Adlard PA; Crack PJ. 2014. Type-1 interferon signaling mediates neuro-inflammatory events in models of Alzheimer's disease.. In: . . MGI: J:212738
Thomas P; Wang YJ; Zhong JH; Kosaraju S; O'Callaghan NJ; Zhou XF; Fenech M. 2009. Grape seed polyphenols and curcumin reduce genomic instability events in a transgenic mouse model for Alzheimer's disease.. In: . . MGI: J:145012
Tian Y; Chang JC; Fan EY; Flajolet M; Greengard P. 2013. Adaptor complex AP2/PICALM, through interaction with LC3, targets Alzheimer's APP-CTF for terminal degradation via autophagy.. In: . . MGI: J:202011
Toba J; Nikkuni M; Ishizeki M; Yoshii A; Watamura N; Inoue T; Ohshima T. 2016. PPARgamma agonist pioglitazone improves cerebellar dysfunction at pre-Abeta deposition stage in APPswe/PS1dE9 Alzheimer's disease model mice.. In: . . MGI: J:235191
Town T; Laouar Y; Pittenger C; Mori T; Szekely CA; Tan J; Duman RS; Flavell RA. 2008. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology.. In: . . MGI: J:137043
Turdi S; Guo R; Huff AF; Wolf EM; Culver B; Ren J. 2009. Cardiomyocyte contractile dysfunction in the APPswe/PS1dE9 mouse model of Alzheimer's disease.. In: . . MGI: J:150191
Um JW; Kaufman AC; Kostylev M; Heiss JK; Stagi M; Takahashi H; Kerrisk ME; Vortmeyer A; Wisniewski T; Koleske AJ; Gunther EC; Nygaard HB; Strittmatter SM. 2013. Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer abeta oligomer bound to cellular prion protein.. In: . . MGI: J:201741
Um JW; Nygaard HB; Heiss JK; Kostylev MA; Stagi M; Vortmeyer A; Wisniewski T; Gunther EC; Strittmatter SM. 2012. Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons.. In: . . MGI: J:190064
Viana da Silva S; Haberl MG; Zhang P; Bethge P; Lemos C; Goncalves N; Gorlewicz A; Malezieux M; Goncalves FQ; Grosjean N; Blanchet C; Frick A; Nagerl UV; Cunha RA; Mulle C. 2016. Early synaptic deficits in the APP/PS1 mouse model of Alzheimer's disease involve neuronal adenosine A2A receptors.. In: . . MGI: J:239884
Volianskis A; Kostner R; Molgaard M; Hass S; Jensen MS. 2010. Episodic memory deficits are not related to altered glutamatergic synaptic transmission and plasticity in the CA1 hippocampus of the APPswe/PS1DeltaE9-deleted transgenic mice model of beta-amyloidosis.. In: . . MGI: J:139071
Vollert C; Forkuo GS; Bond RA; Eriksen JL. 2013. Chronic treatment with DCPCX, an adenosine A(1) antagonist, worsens long-term memory.. In: . . MGI: J:201537
Wang BJ; Her GM; Hu MK; Chen YW; Tung YT; Wu PY; Hsu WM; Lee H; Jin LW; Hwang SL; Chen RP; Huang CJ; Liao YF. 2017. ErbB2 regulates autophagic flux to modulate the proteostasis of APP-CTFs in Alzheimer's disease.. In: . . MGI: J:242145
Wang CY; Wang T; Zheng W; Zhao BL; Danscher G; Chen YH; Wang ZY. 2010. Zinc overload enhances APP cleavage and Abeta deposition in the Alzheimer mouse brain.. In: . . MGI: J:168997
Wang CY; Wang ZY; Xie JW; Wang T; Wang X; Xu Y; Cai JH. 2016. Dl-3-n-butylphthalide-induced upregulation of antioxidant defense is involved in the enhancement of cross talk between CREB and Nrf2 in an Alzheimer's disease mouse model.. In: . . MGI: J:234516
Wang F; Liu H; Shen X; Ao H; Moore N; Gao L; Chen L; Hu H; Ma H; Yang Z; Zhai C; Qin J; Zhou G; Peng Y; Feng X; Li R; Liang C. 2015. The combined treatment of amyloid-beta(1)(-)(4)(2)-stimulated bone marrow-derived dendritic cells plus splenocytes from young mice prevents the development of Alzheimer's disease in APPswe/PSENldE9 mice.. In: . . MGI: J:218109
Wang H; Liu J; Zong Y; Xu Y; Deng W; Zhu H; Liu Y; Ma C; Huang L; Zhang L; Qin C. 2010. miR-106b aberrantly expressed in a double transgenic mouse model for Alzheimer's disease targets TGF-beta type II receptor.. In: . . MGI: J:165149
Wang J; Lu R; Yang J; Li H; He Z; Jing N; Wang X; Wang Y. 2015. TRPC6 specifically interacts with APP to inhibit its cleavage by gamma-secretase and reduce Abeta production.. In: . . MGI: J:228025
Wang J; Shan C; Cao W; Zhang C; Teng J; Chen J. 2013. SCG10 promotes non-amyloidogenic processing of amyloid precursor protein by facilitating its trafficking to the cell surface.. In: . . MGI: J:203138
Wang L; Chiang HC; Wu W; Liang B; Xie Z; Yao X; Ma W; Du S; Zhong Y. 2012. Epidermal growth factor receptor is a preferred target for treating amyloid-beta-induced memory loss.. In: . . MGI: J:190314
Wang P; Guan PP; Guo JW; Cao LL; Xu GB; Yu X; Wang Y; Wang ZY. 2016. Prostaglandin I2 upregulates the expression of anterior pharynx-defective-1alpha and anterior pharynx-defective-1beta in amyloid precursor protein/presenilin 1 transgenic mice.. In: . . MGI: J:236114
Wang Q; Xu Y; Chen JC; Qin YY; Liu M; Liu Y; Xie MJ; Yu ZY; Zhu Z; Wang W. 2012. Stromal cell-derived factor 1alpha decreases beta-amyloid deposition in Alzheimer's disease mouse model.. In: . . MGI: J:186448
Wang R; Palavicini JP; Wang H; Maiti P; Bianchi E; Xu S; Lloyd BN; Dawson-Scully K; Kang DE; Lakshmana MK. 2014. RanBP9 overexpression accelerates loss of dendritic spines in a mouse model of Alzheimer's disease.. In: . . MGI: J:214745
Wang SW; Yang SG; Liu W; Zhang YX; Xu PX; Wang T; Ling TJ; Liu RT. 2016. Alpha-tocopherol quinine ameliorates spatial memory deficits by reducing beta-amyloid oligomers, neuroinflammation and oxidative stress in transgenic mice with Alzheimer's disease.. In: . . MGI: J:227505
Wang YJ; Wang X; Lu JJ; Li QX; Gao CY; Liu XH; Sun Y; Yang M; Lim Y; Evin G; Zhong JH; Masters C; Zhou XF. 2011. p75NTR regulates Abeta deposition by increasing Abeta production but inhibiting Abeta aggregation with its extracellular domain.. In: . . MGI: J:169451
Weekman EM; Sudduth TL; Caverly CN; Kopper TJ; Phillips OW; Powell DK; Wilcock DM. 2016. Reduced Efficacy of Anti-Abeta Immunotherapy in a Mouse Model of Amyloid Deposition and Vascular Cognitive Impairment Comorbidity.. In: . . MGI: J:235564
Weitz TM; Gate D; Rezai-Zadeh K; Town T. 2014. MyD88 Is Dispensable for Cerebral Amyloidosis and Neuroinflammation in APP/PS1 Transgenic Mice.. In: . . MGI: J:216385
West MJ; Bach G; Soderman A; Jensen JL. 2009. Synaptic contact number and size in stratum radiatum CA1 of APP/PS1DeltaE9 transgenic mice.. In: . . MGI: J:152954
Wirz KT; Bossers K; Stargardt A; Kamphuis W; Swaab DF; Hol EM; Verhaagen J. 2013. Cortical beta amyloid protein triggers an immune response, but no synaptic changes in the APPswe/PS1dE9 Alzheimer's disease mouse model.. In: . . MGI: J:203377
Woodling NS; Wang Q; Priyam PG; Larkin P; Shi J; Johansson JU; Zagol-Ikapitte I; Boutaud O; Andreasson KI. 2014. Suppression of Alzheimer-associated inflammation by microglial prostaglandin-E2 EP4 receptor signaling.. In: . . MGI: J:210613
Wu H; Williams J; Nathans J. 2014. Complete morphologies of basal forebrain cholinergic neurons in the mouse.. In: . . MGI: J:213265
Wu J; Fu B; Lei H; Tang H; Wang Y. 2016. Gender differences of peripheral plasma and liver metabolic profiling in APP/PS1 transgenic AD mice.. In: . . MGI: J:238137
Wu Y; Ma Y; Liu Z; Geng Q; Chen Z; Zhang Y. 2017. Alterations of myelin morphology and oligodendrocyte development in early stage of Alzheimer's disease mouse model.. In: . . MGI: J:242089
Xiao Q; Gil SC; Yan P; Wang Y; Han S; Gonzales E; Perez R; Cirrito JR; Lee JM. 2012. Role of phosphatidylinositol clathrin assembly lymphoid-myeloid leukemia (PICALM) in intracellular amyloid precursor protein (APP) processing and amyloid plaque pathogenesis.. In: . . MGI: J:186509
Xiao Z; Cilz NI; Kurada L; Hu B; Yang C; Wada E; Combs CK; Porter JE; Lesage F; Lei S. 2014. Activation of neurotensin receptor 1 facilitates neuronal excitability and spatial learning and memory in the entorhinal cortex: beneficial actions in an Alzheimer's disease model.. In: . . MGI: J:211262
Xie H; Guan J; Borrelli LA; Xu J; Serrano-Pozo A; Bacskai BJ. 2013. Mitochondrial alterations near amyloid plaques in an Alzheimer's disease mouse model.. In: . . MGI: J:204673
Xu G; Green CC; Fromholt SE; Borchelt DR. 2012. Reduction of low-density lipoprotein receptor-related protein (LRP1) in hippocampal neurons does not proportionately reduce, or otherwise alter, amyloid deposition in APPswe/PS1dE9 transgenic mice.. In: . . MGI: J:190171
Xu G; Karch C; Li N; Lin N; Fromholt D; Gonzales V; Borchelt DR. 2008. Receptor-associated protein (RAP) plays a central role in modulating Abeta deposition in APP/PS1 transgenic mice.. In: . . MGI: J:143942
Xu G; Stevens SM Jr; Moore BD; McClung S; Borchelt DR. 2013. Cytosolic proteins lose solubility as amyloid deposits in a transgenic mouse model of Alzheimer-type amyloidosis.. In: . . MGI: J:198545
Xu Y; Wang D; Luo Y; Li W; Shan Y; Tan X; Zhu C. 2015. Beta amyloid-induced upregulation of death receptor 6 accelerates the toxic effect of N-terminal fragment of amyloid precursor protein.. In: . . MGI: J:218312
Xu Z; Dong Y; Wang H; Culley DJ; Marcantonio ER; Crosby G; Tanzi RE; Zhang Y; Xie Z. 2014. Age-dependent postoperative cognitive impairment and Alzheimer-related neuropathology in mice.. In: . . MGI: J:210096
Yan J; Liu XH; Han MZ; Wang YM; Sun XL; Yu N; Li T; Su B; Chen ZY. 2015. Blockage of GSK3beta-mediated Drp1 phosphorylation provides neuroprotection in neuronal and mouse models of Alzheimer's disease.. In: . . MGI: J:218439
Yanagisawa D; Ibrahim NF; Taguchi H; Morikawa S; Hirao K; Shirai N; Sogabe T; Tooyama I. 2015. Curcumin derivative with the substitution at C-4 position, but not curcumin, is effective against amyloid pathology in APP/PS1 mice.. In: . . MGI: J:218307
Yang GZ; Yang M; Lim Y; Lu JJ; Wang TH; Qi JG; Zhong JH; Zhou XF. 2012. Huntingtin associated protein 1 regulates trafficking of the amyloid precursor protein and modulates amyloid beta levels in neurons.. In: . . MGI: J:187639
Yang H; Yang H; Xie Z; Wei L; Bi J. 2013. Systemic transplantation of human umbilical cord derived mesenchymal stem cells-educated T regulatory cells improved the impaired cognition in AbetaPPswe/PS1dE9 transgenic mice.. In: . . MGI: J:204355
Yang SG; Wang SW; Zhao M; Zhang R; Zhou WW; Li YN; Su YJ; Zhang H; Yu XL; Liu RT. 2012. A peptide binding to the beta-site of APP improves spatial memory and attenuates Abeta burden in Alzheimer's disease transgenic mice.. In: . . MGI: J:195596
Yang W; Zhou X; Zimmermann HR; Cavener DR; Klann E; Ma T. 2016. Repression of the eIF2alpha kinase PERK alleviates mGluR-LTD impairments in a mouse model of Alzheimer's disease.. In: . . MGI: J:235030
Yang YJ; Zhao Y; Yu B; Xu GG; Wang W; Zhan JQ; Tang ZY; Wang T; Wei B. 2016. GluN2B-containing NMDA receptors contribute to the beneficial effects of hydrogen sulfide on cognitive and synaptic plasticity deficits in APP/PS1 transgenic mice.. In: . . MGI: J:238229
Yeh CW; Yeh SH; Shie FS; Lai WS; Liu HK; Tzeng TT; Tsay HJ; Shiao YJ. 2015. Impaired cognition and cerebral glucose regulation are associated with astrocyte activation in the parenchyma of metabolically stressed APPswe/PS1dE9 mice.. In: . . MGI: J:232255
Yoshiike Y; Kimura T; Yamashita S; Furudate H; Mizoroki T; Murayama M; Takashima A. 2008. GABA(A) receptor-mediated acceleration of aging-associated memory decline in APP/PS1 mice and its pharmacological treatment by picrotoxin.. In: . . MGI: J:139681
Yu X; Guan PP; Guo JW; Wang Y; Cao LL; Xu GB; Konstantopoulos K; Wang ZY; Wang P. 2015. By suppressing the expression of anterior pharynx-defective-1alpha and -1beta and inhibiting the aggregation of beta-amyloid protein, magnesium ions inhibit the cognitive decline of amyloid precursor protein/presenilin 1 transgenic mice.. In: . . MGI: J:230598
Yun SM; Cho SJ; Song JC; Song SY; Jo SA; Jo C; Yoon K; Tanzi RE; Choi EJ; Koh YH. 2013. SUMO1 modulates Abeta generation via BACE1 accumulation.. In: . . MGI: J:194511
Zamora E; Handisurya A; Shafti-Keramat S; Borchelt D; Rudow G; Conant K; Cox C; Troncoso JC; Kirnbauer R. 2006. Papillomavirus-like particles are an effective platform for amyloid-beta immunization in rabbits and transgenic mice.. In: . . MGI: J:138349
Zelcer N; Khanlou N; Clare R; Jiang Q; Reed-Geaghan EG; Landreth GE; Vinters HV; Tontonoz P. 2007. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors.. In: . . MGI: J:122372
Zerbi V; Jansen D; Wiesmann M; Fang X; Broersen LM; Veltien A; Heerschap A; Kiliaan AJ. 2014. Multinutrient diets improve cerebral perfusion and neuroprotection in a murine model of Alzheimer's disease.. In: . . MGI: J:212742
Zerbi V; Kleinnijenhuis M; Fang X; Jansen D; Veltien A; Van Asten J; Timmer N; Dederen PJ; Kiliaan AJ; Heerschap A. 2013. Gray and white matter degeneration revealed by diffusion in an Alzheimer mouse model.. In: . . MGI: J:203373
Zhang LH; Wang X; Zheng ZH; Ren H; Stoltenberg M; Danscher G; Huang L; Rong M; Wang ZY. 2010. Altered expression and distribution of zinc transporters in APP/PS1 transgenic mouse brain.. In: . . MGI: J:156810
Zhang MY; Zheng CY; Zou MM; Zhu JW; Zhang Y; Wang J; Liu CF; Li QF; Xiao ZC; Li S; Ma QH; Xu RX. 2014. Lamotrigine attenuates deficits in synaptic plasticity and accumulation of amyloid plaques in APP/PS1 transgenic mice.. In: . . MGI: J:218119
Zhang P; Xie MQ; Ding YQ; Liao M; Qi SS; Chen SX; Gu QQ; Zhou P; Sun CY. 2015. Allopregnanolone enhances the neurogenesis of midbrain dopaminergic neurons in APPswe/PSEN1 mice.. In: . . MGI: J:224573
Zhang Q; Zhang X; Chen J; Miao Y; Sun A. 2009. Role of caspase-3 in tau truncation at D421 is restricted in transgenic mouse models for tauopathies.. In: . . MGI: J:149265
Zhang W; Bai M; Xi Y; Hao J; Liu L; Mao N; Su C; Miao J; Li Z. 2012. Early memory deficits precede plaque deposition in APPswe/PS1dE9 mice: Involvement of oxidative stress and cholinergic dysfunction.. In: . . MGI: J:182600
Zhang W; Bai M; Xi Y; Hao J; Zhang Z; Su C; Lei G; Miao J; Li Z. 2012. Multiple inflammatory pathways are involved in the development and progression of cognitive deficits in APPswe/PS1dE9 mice.. In: . . MGI: J:191173
Zhang W; Hao J; Liu R; Zhang Z; Lei G; Su C; Miao J; Li Z. 2011. Soluble Abeta levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.. In: . . MGI: J:172201
Zhang X; Luhrs KJ; Ryff KA; Malik WT; Driscoll MJ; Culver B. 2009. Suppression of nuclear factor kappa B ameliorates astrogliosis but not amyloid burden in APPswe/PS1dE9 mice.. In: . . MGI: J:152589
Zhang X; Tian Y; Zhang C; Tian X; Ross AW; Moir RD; Sun H; Tanzi RE; Moore A; Ran C. 2015. Near-infrared fluorescence molecular imaging of amyloid beta species and monitoring therapy in animal models of Alzheimer's disease.. In: . . MGI: J:226047
Zhang Y; Zhou B; Deng B; Zhang F; Wu J; Wang Y; Le Y; Zhai Q. 2013. Amyloid-beta induces hepatic insulin resistance in vivo via JAK2.. In: . . MGI: J:208594
Zhang Y; Zhou B; Zhang F; Wu J; Hu Y; Liu Y; Zhai Q. 2012. Amyloid-beta induces hepatic insulin resistance by activating JAK2/STAT3/SOCS-1 signaling pathway.. In: . . MGI: J:196823
Zhang Z; Goldschmidt T; Salter H. 2012. Possible allelic structure of IgG2a and IgG2c in mice.. In: . . MGI: J:181369
Zhang Z; Song M; Liu X; Su Kang S; Duong DM; Seyfried NT; Cao X; Cheng L; Sun YE; Ping Yu S; Jia J; Levey AI; Ye K. 2015. Delta-secretase cleaves amyloid precursor protein and regulates the pathogenesis in Alzheimer's disease.. In: . . MGI: J:228032
Zhen G; Kim YT; Li RC; Yocum J; Kapoor N; Langer J; Dobrowolski P; Maruyama T; Narumiya S; Dore S. 2012. PGE2 EP1 receptor exacerbated neurotoxicity in a mouse model of cerebral ischemia and Alzheimer's disease.. In: . . MGI: J:188185
Zheng W; Xin N; Chi ZH; Zhao BL; Zhang J; Li JY; Wang ZY. 2009. Divalent metal transporter 1 is involved in amyloid precursor protein processing and Abeta generation.. In: . . MGI: J:155170
Zhou WW; Lu S; Su YJ; Xue D; Yu XL; Wang SW; Zhang H; Xu PX; Xie XX; Liu RT. 2014. Decreasing oxidative stress and neuroinflammation with a multifunctional peptide rescues memory deficits in mice with Alzheimer disease.. In: . . MGI: J:220049
Zhou X; Hu X; He W; Tang X; Shi Q; Zhang Z; Yan R. 2011. Interaction between amyloid precursor protein and Nogo receptors regulates amyloid deposition.. In: . . MGI: J:175718
Zhu X; Ye L; Ge H; Chen L; Jiang N; Qian L; Li L; Liu R; Ji S; Zhang S; Jin J; Guan D; Fang W; Tan R; Xu Y. 2013. Hopeahainol A attenuates memory deficits by targeting beta-amyloid in APP/PS1 transgenic mice.. In: . . MGI: J:214932
Zhu Y; Hou H; Rezai-Zadeh K; Giunta B; Ruscin A; Gemma C; Jin J; Dragicevic N; Bradshaw P; Rasool S; Glabe CG; Ehrhart J; Bickford P; Mori T; Obregon D; Town T; Tan J. 2011. CD45 Deficiency Drives Amyloid-{beta} Peptide Oligomers and Neuronal Loss in Alzheimer's Disease Mice.. In: . . MGI: J:168546

Also Known As: APP/PS1

Donating Investigator

Genetic overview

Research Applications

Detailed Description

Development

Expression Data

Control Suggestions

Additional Information

Selected References

Tg(APPswe,PSEN1dE9)85Dbo

Allele Symbol: Tg(APPswe,PSEN1dE9)85Dbo

Disease Terms

Research Areas By Genotype

This mouse can be used to support research in many areas including:

Genotype: APP related

Genotype: Tg(APPswe,PSEN1dE9)85Dbo related

Mammalian Phenotype Terms by Genotype

Genotype: Tg(APPswe,PSEN1dE9)85Dbo/0B6C3-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax

nervous system phenotype

behavior/neurological phenotype

homeostasis/metabolism phenotype

cardiovascular system phenotype

growth/size/body region phenotype

Genotype: Tg(APPswe,PSEN1dE9)85Dbo/0involves: C3H/HeJ * C57BL/6J

nervous system phenotype

behavior/neurological phenotype

growth/size/body region phenotype

homeostasis/metabolism phenotype

Genotype: Tg(APPswe,PSEN1dE9)85Dbo/0involves: C3H * C57BL/6

nervous system phenotype

homeostasis/metabolism phenotype

Genotype: Tg(APPswe,PSEN1dE9)85Dbo/0D2.Cg-Tg(APPswe,PSEN1dE9)85Dbo

homeostasis/metabolism phenotype

hematopoietic system phenotype

mortality/aging

immune system phenotype

behavior/neurological phenotype

nervous system phenotype

Genotype: Tg(APPswe,PSEN1dE9)85Dbo/0B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax

mortality/aging

behavior/neurological phenotype

nervous system phenotype

taste/olfaction phenotype

homeostasis/metabolism phenotype

Genotype: Hc1/Hc1 Tg(APPswe,PSEN1dE9)85Dbo/0D2.Cg-Tg(APPswe,PSEN1dE9)85Dbo

homeostasis/metabolism phenotype

behavior/neurological phenotype

mortality/aging

nervous system phenotype

References

Additional References

Additional - Tg(APPswe,PSEN1dE9)85Dbo related

Genotyping Protocols

Breeding Considerations

Mating System

Citation

Animal Health Reports

Terms of Use

Additional Use Restrictions Apply

Licensing Information

JAX® Mice, Products & Services Conditions of Use

No Warranty

Credit for PRODUCTS or SERVICES

Animal Care and Use for SERVICES

No Liability

Genotype: Tg(APPswe,PSEN1dE9)85Dbo/0
B6C3-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax

Genotype: Tg(APPswe,PSEN1dE9)85Dbo/0
involves: C3H/HeJ * C57BL/6J

Genotype: Tg(APPswe,PSEN1dE9)85Dbo/0
involves: C3H * C57BL/6

Genotype: Tg(APPswe,PSEN1dE9)85Dbo/0
D2.Cg-Tg(APPswe,PSEN1dE9)85Dbo

Genotype: Tg(APPswe,PSEN1dE9)85Dbo/0
B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax

Genotype: Hc¹/Hc¹ Tg(APPswe,PSEN1dE9)85Dbo/0
D2.Cg-Tg(APPswe,PSEN1dE9)85Dbo